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ABSTRACT 
 
Background 
Chlamydial infection is the most common bacterial genital infection in the US with 1,244,180 cases 
documented in 2009. There are likely additional unreported cases because of presumptive treatment of 
disease, asymptomatic nature of genital infection, and lack of access to medical care. In 2007, the 
USPSTF published a recommendation statement to screen all sexually active nonpregnant women age 24 
years or younger and older nonpregnant women at increased risk. Because of a lack of direct evidence on 
the effect of screening in men to reduce transmission to women, in reducing reinfection rates in men, or in 
preventing adverse health outcomes for men, they refrain from recommended for or against screening, 
leaving primary care clinicians and STD prevention programs with little guidance in practice. 
 
Objectives 
This systematic review was conducted to update the evidence for screening the sexually transmitted 
bacterial disease (STD), Chlamydia trachomatis in men, the screening effect on improving health 
outcomes, the evidence on the harms of screening and adverse events from treatment in men. This review 
will not assess existing recommendations that the USPSTF have already deemed ―good‖ or ―fair‖.   
 
Qualitative Methods 
An analytic framework was developed by adapting the previously published work by the USPSTF on 
screening for Chlamydia infections in young women.  From the framework, four key questions were 
developed to guide the literature search of articles published in PubMed-MEDLINE from 2000 through 
September 2010 and in the Cochrane Database of Systematic Review. Results were abstracted into tables, 
reviewed and assessed for methodological quality using criteria adapted from the STROBE statement.  
 
Results 
A total of 497 titles and abstracts were found from the initial search of databases plus 4 hand-selected 
articles from references of relevant articles. The final 8 articles that met all criteria were abstracted for 
data and rated for quality.  
The search produced one ―fair‖ but inconclusive study examining the effect of screening on disease 
frequency and no studies on changes in disease morbidity and mortality with screening. Two studies 
pertaining to positivity rates found significantly higher rates in men aged 19-24 and black Caribbean and 
unspecified black background. One fair and one good study found only mild to moderate harms from 
screening to conclude that benefits to screening were greater than the mild psychological harms. Lastly, 
one good meta-analysis concluded that doxycycline and azithromycin are equally efficacious in the 
treatment for Chlamydia in men and women with mild side effects including diarrhea, abdominal pain, 
and nausea. 
 
Conclusions 
There continues to be a lack of evidence on the effectiveness of lowering disease frequency, mortality and 
morbidity in women by screening asymptomatic men. Even while non-harmful screening tests and 
effective treatment of chlamydial infection are available, there is insufficient data to recommend any 
screening strategies of asymptomatic men at this time. 
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INTRODUCTION 
 
Scope and Purpose 
This systematic review was conducted to update the United States Preventive Services 
Task Force (USPSTF) review commissioned to search the evidence for screening the sexually 
transmitted bacterial disease (STD), Chlamydia trachomatis in 2001.
1
  In 2005, the USPSTF 
deemed an evidence update was necessary to strengthen weak recommendations and fill gaps in 
evidence, and in 2007 a focused review was published.
2
  Based on the two reviews conducted, 
the USPSTF concluded that good direct evidence existed to recommend non-pregnant females to 
receive screening for Chlamydia to reduce adverse health outcomes.  However, due to the 
continued lack of evidence, the USPSTF was not able to make any new recommendation for 
screening men for chlamydial infection. 
The focus of this review is to search for new evidence and synthesize the research with 
previously published review articles and update the recommendations for Chlamydia screening 
in men.  This review will not assess the existing recommendations that the USPSTF have 
deemed ―Good‖ or ―Fair,‖ such as the evidence to screen non-pregnant or pregnant women.  
Likewise, this review will not cover the efficacy of infection treatment.  Rather, this review will 
update the evidence on screening programs for men and its effect on improving health outcomes 
through improved prevalence and improved health outcomes for men and women in the 
population as well as examine evidence on the harms of screening and adverse events from 
treatment in men. 
Prevalence and Burden of Suffering 
Chlamydial infection is the most common bacterial genital infection in the United States.
3
  
Since the Centers for Disease Control and Prevention (CDC) first surveyed the incident cases in 
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1941, Chlamydia has been documented as the most frequently reported STD in the US, nearly 
quadrupling the rate of syphilis, gonorrhea, and chancroid combined.
3
  Table 1 below shows the 
upward trend of reported disease in the U.S.  However, interpretation of the rising incidence 
poses the epidemiological challenge of determining actual trends of disease prevalence in the 
community because increased screening seen in the last two decades leads to increased disease 
detection. However, the recent upward trend of Chlamydia is alarming; and even with 
recommended screening in women 25 and under, trends may indicate a persistent and high 
prevalence of chlamydial infection in the U.S population.  
 
Figure 1. Chlamydia cases reported by state department: United States, 1984-2008* 
 
 Data from CDC, Sexually Transmitted Disease Surveillance, 2008. 
 
The most recent surveillance report published in 2009 reported the highest number of 
cases ever documented at 1,244,180, and there are likely additional cases unreported or 
undiagnosed because of various factors, including presumptive treatment of disease, 
asymptomatic nature of genital infection, and lack of access to medical care.
4
  An estimated 
2,291,000 individuals ages 14-39 were infected with C. trachomatis, based on the U.S. National 
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Health and Nutrition Examination Survey (NHANES).
5
  Prevalence estimates for adolescents 
and young adults have been found to be higher than that of the rest of the population.  The U.S. 
NHANES survey estimated a 2.2% (95% confidence interval [CI] 1.8%-2.8%) prevalence for 
14-39 year-old men and women, while the cross-sectional study of The National Longitudinal 
Study of Adolescent Health
 
cohort of 18-26 year olds found an overall prevalence at 4.19% (95% 
CI, 3.48%-4.90%).
6
  The same study showed that Chlamydia was disproportionately prevalent in 
black women with the highest prevalence of 13.95% (95% CI, 11.25%-17.18%).  In a review of 
published data from national sources including surveys of male adolescents, correctional 
facilities and data from the National Health and Nutrition Examination Survey (NHANES 1999-
2002), the greatest burden of chlamydial infection is among men between ages 20 and 24 years.
7
  
chlamydial infections were disproportionately more prevalent in black and Hispanic men when 
compared to white men. 
In addition to the health effects of genital infection, STDs are also a substantial economic 
burden on the U.S. healthcare system.  The direct costs include clinic visits, diagnostic testing, 
treatment, treatment side effects, medication fees, and the treatment of possible complications 
from disease sequalae.  In 2004, a review was published to estimate the direct costs of STDs in 
the U.S.
8
  Adjusted for the year 2000, the estimated the average cost per case for men was 20 
dollars and for women 244 dollars.  The total cost of chlamydial infection in the US was 
estimated at 250 million dollars per year, making Chlamydia the costliest bacterial STD, after the 
viral STDs HIV and genital herpes.  Another study found that in women, 82% of the cost per 
case is attributable to disease sequelae, whereas among men, 78% of the estimated cost per case 
is attributable to acute infection.
9
  Another study found that indirect costs (wages lost from 
missed work, complications from treatment or missed treatment opportunities, hospitalizations, 
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etc) are as high as 540 million dollars per year.
10
  While cost analyses are often limited, these 
estimations underscore the substantial personal and economic burden of chlamydial infection and 
the necessity of effective preventive strategies to reduce the burden of this disease.  
Natural History  
Chlamydial infection is a sexually transmitted disease caused by the bacterium 
Chlamydia trachomatis.  It causes genital infections in humans and can also manifest as 
trachoma and perinatal infections.
11
  In women, the bacteria proliferate and cause inflammation 
of cervical tissue, or mucopurolent cervicitis and ascend to the fallopian tubes, causing 
salpingitis and pelvic inflammatory disease (PID).
12
  Subsequent reinfection or prolonged 
untreated infection causes scar tissue to form around the inflamed tissue.
13
  Once symptomatic 
PID has occurred, there is a 1 in 6 chance a women will develop infertility.
14,15
 There is also risk 
of developing bartholinitis and Fitz-Hugh-Curtis syndrome (perihepatitis).
11
 While in men 
symptoms and sequelae are less frequent, C.trachomatis can cause nongonococcal urethritis 
(NGU), proctitis, and epididymitis.  Up to 42% of NGU infections are asymptomatic, increasing 
the likelihood of transmission of the infection.
16
  
 Human studies on the natural course of chlamydial infections are limited, but it is 
generally accepted that untreated infection can spontaneously clear over a period of months to 
years.
17
  However, reinfection does occur in women 20% at one year, increasing the likelihood of 
complications.
18,19,20
 Another recent prospective study of women aged 14-17 found a reinfection 
rate as high as 31.3% over three years.
21
 
Risk Factors for Chlamydial Infection 
Sexually active individuals are at risk for acquiring chlamydial infection.  While the 
infection can be acquired at any age, the highest rates occur in the late teens and early twenties.  
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Other risk factors include frequent changing of sexual partners, two or more sexual partners in a 
year, and a recent change in partner.
22
  According to surveillance data, the highest rates of 
chlamydial infection have been in the Southeast and West regions in the U.S.  Also, higher 
incidence rates have been reported for women in all 50 states, almost three times the rate of men 
overall, which can most likely be attributed to the emphasis of screening programs directed 
towards women.  The surveillance data also demonstrate increased chlamydial infection rates 
among blacks whose rates are eight times that of whites (1,519.3 cases per 100,000 in blacks 
compared to 173.6 in whites).
3 
Less is known about the risk factors for chlamydial infection in men than in women.  A 
Dutch study based on 21,000 men and women found chlamydial infection in men was associated 
with younger age, multiple sex partners, low education, low condom use, and complaints of 
frequent urination.
23
  
Management of Infection 
Treatment of Infected Person 
Two recommended regimens exist for the treatment of uncomplicated cases of 
chlamydial infection.  A single oral dose of azithromycin (1 gram) or a seven-day course of 
doxycycline have been shown to be equivalent in both efficacy and tolerability and have shown a 
92.1-97% effectiveness in various studies.
24, 25, 26, 27
  Longer courses of antibiotic regimens are 
required to treat complicated chlamydial infections such as PID and epididymitis.  
Treatment of Sex Partners 
Approximately 57-75% of partners of infected individuals are infected with Chlamydia 
themselves.
28,29
  Partner notification programs have seen less than optimal results, likely due to 
the stigma associated with infection, differences in cultural beliefs between partners, and other 
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relationship dynamics.
29
  While out of the scope of this paper to provide guidelines for partner 
notification and treatment through patient or provider referrals, it is obvious that the evaluation 
and treatment of partners is an important component in controlling chlamydial infection in the 
population. 
Levels of Prevention and Screening 
 Clinical practice should target various levels of strategies for STI prevention. The CDC 
recognizes three levels of prevention: primary, secondary, and tertiary STD prevention.
30
  
Strategies for primary prevention of STI focus on prior to incidence or acquisition of disease and 
including public education, ad campaigns and billboards, and barrier methods such as condoms. 
Secondary prevention strategies aim to diagnose and treat an infected patient, such as universal 
screening of females for Chlamydia, and treatment with positive testing. Finally, tertiary 
prevention focuses on limiting complications and other negative health effects from disease such 
as treatment for PID and infertility. 
 There are a limited number of studies on primary prevention methods, especially in the 
high-risk youth population, but there are numerous studies on secondary and tertiary 
interventions for screening methods, treatment of STIs and management of their complications.
31
 
Specifically, Chlamydia screening programs have been found to decrease disease burden and 
long-term health consequences, decreasing prevalence of complications like pelvic inflammatory 
disease by 60%.
32
 Also, because the asymptomatic nature of chlamydial infection, screening, 
diagnosing, and treatment of unrecognized infection could prevent further transmission of 
disease. Further, screening tests are relatively rapid, affordable, and minimally invasive, 
especially if collected by urine. With these screening tools available for the detection of 
Chlamydia, it is important to continue to refine screening programs and to ensure that 
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appropriate high-risk populations are targeted to effectively reduce the disease burden in the 
population.  
Current Recommendations by the USPSTF 
In 2007, the USPSTF published a recommendation statement for screening for 
chlamydial infection.  They recommend to screen for chlamydial infection in all sexually active 
nonpregnant young women age 24 years or younger and for older nonpregnant women who are 
at increased risk (A recommendation).  Secondly, they recommend to screen for chlamydial 
infection in all pregnant women age 24 years or younger and in older pregnant women who are 
at increased risk (B recommendation).  
The USPSTF recommend against routinely screening for chlamydial infection in women 
age 25 years or older, regardless of whether they are pregnant, if they are not at increased risk (C 
recommendation).  
Lastly, they conclude that the evidence is insufficient to recommend for, or against 
routine screening of men due to the inability to assess the balance of benefits and harms of 
screening men (I statement).
33
  See Appendix A for USPSTF recommendation grading system. 
Current Practice 
 
Because most cases of chlamydial infections are asymptomatic, US Chlamydia control 
programs have focused on opportunistic screening of the higher risk age groups to diagnose and 
treat infection.  Screening can be performed during routine physical exam visits, emergency 
room encounters, contraceptive counseling appointments, and primary care evaluations. 
Current chlamydial infection screening rates are low, estimated at 41.6% among sexually 
active females aged 16-25 years according to a review of the Healthcare Effectiveness Data and 
Information Set (HEDIS) conducted by the CDC in 2007.
34
  The highest regional rate of 
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chlamydial infection screening in 2007 was in the Northeast (45.5%) and the lowest was in the 
South (37.3%), with some states as low as 20%.  The HEDIS is used by 90.0% of U.S. health 
plans to evaluate the quality of health-care services and benchmark performance and is a reliable 
data source for insured populations in the US.  However, it is estimated that 18.4% of females 
aged 16−20 years and 28.2% aged 21−25 years were uninsured in 2007, meaning up to 4.8 
million young women were less likely to access care and less likely to have resources to pay for 
chlamydial infection screening.
35,36
  
Currently, it is recommended that all patients who have confirmed or suspected urethritis 
receive testing for gonorrhea and chlamydial infection because of the increased utility and 
availability of highly sensitive and specific testing methods and because a specific diagnosis 
might enhance partner notification and improve compliance with treatment, especially in the 
exposed partner.
37
 Treatment should be initiated as soon as possible after diagnosis.  
Population-based cross-sectional studies have found high prevalence range of 6.8-10.1% 
in adolescent and young men. 
38,39
   Even so, there are no recommendations for routine screening 
to detect infection in asymptomatic men for Chlamydia in the U.S.   
Chlamydial Screening Tests 
The previous USPSTF review found reliable and valid methods to screen and diagnose 
chlamydial infection in men.
1
 Culture analysis of urethral swab specimens is considered the 
diagnostic gold standard for chlamydial infection.  However, acceptability of this mode of 
screening by patients and providers is restricted due to high expense, limited availability, a wait 
of 3 to 5 days for results, and the discomfort associated with invasive sampling.
40
  
Nonculture antigen-detection tests (direct fluorescent antibody [DFA] assay and enzyme 
immunoassay [EIA]) and nonamplified nucleic acid hybridization based on DNA and RNA 
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technology are used in clinic as well, but still require invasive swabs for men to obtain 
specimens.
1
 
Tests using urine samples provide a more acceptable method of noninvasive specimen 
collection for both men and women.  Accurate, reliable, and valid tests antigen-detection tests 
and DNA and RNA amplification tests are also available.  A disadvantage of the amplification 
tests is that Chlamydia DNA can be detected up to 21 days after treatment because of the 
presence of nonviable organisms, possibly affecting test of cure or reinfection rates.
41
 
Rationale for Chlamydial Screening in Men 
A significant proportion of males and females infected with C. trachomatis are 
asymptomatic and do not seek testing or treatment.  Unless they are screened, these individuals 
provide an ongoing reservoir for infection with the potential to transmit infection to partners and 
reinfect themselves.  Without routine screening, most infections identified and treated among 
men are the result of symptomatic management or diagnostic testing
42
 or through referrals from 
provider or partner notification programs.
43
  However, increasing rates of chlamydial infection 
and high rates of reinfection question the effectiveness of current screening practices to control 
and reduce the burden of disease.  Testing only women is not sufficient to reduce the prevalence 
in high-risk populations.  As men have a role in the transmission and reinfection of infection in 
women, screening men is a logical strategy to reduce the overall burden of disease.  
Controversies about Chlamydial Screening in Men 
 
Although screening for chlamydial infection among men can lead to increased treatment 
in women and can theoretically lead to reduced infection rates in women by reduced 
transmission, evidence that the burden of disease in women decreases when men are screened 
has been lacking.  Instead the USPSTF reached different conclusions about chlamydial infection 
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screening in men, concluding that control programs should focus on improving the low rates of 
screening in women.
2
 The USPSTF concluded that there is a lack of direct evidence on the effect 
of screening and treatment in men to reduce transmission to women, in reducing reinfection rates 
in men, or in preventing adverse health outcomes for men.  This lack of recommendation for or 
against screening has left primary care clinicians and STD prevention programs with little 
guidance to inform approaches to screening men for chlamydial infection.   
Therefore, it is critical to fill evidence gaps by reinvestigating the literature.  This paper 
will update the recommendations with new evidence on screening for chlamydial infection in 
men. Throughout this paper, the term Chlamydia will be used to mean C. trachomatis genital 
infection. 
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METHODS 
This section of the review documents the literature search process used to develop and 
collect the evidence on screening men for the sexually transmitted infection, Chlamydia.  Below 
we document the inclusion and exclusion criteria, Medical Subject Headings (MeSH terms) used, 
describe data abstraction methods, and how evidence tables were developed and analyzed.  In all 
these steps, the author was the sole reader and abstractor of the evidence.  
Analytic Framework 
The analytic framework (Figure 2) was developed by adapting the previously published 
work by the USPSTF on screening for Chlamydia infections in young women.  From the 
framework, four key questions (KQ) numbered below were developed to guide the literature 
search of gaps in evidence required to update the USPSTF recommendations.  
 
Figure 2. Analytic Framework for Chlamydia Screening in Men 
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Critical Key Questions 
 
 
 
 
 
 
 
Key questions, which guided the literature review, were identified as areas with 
unresolved issues since the previous USPSTF recommendations.  Questions not included in this 
review are accuracy of screening instruments used or the efficacy of treatment in men as 
previous reviews have found sufficient evidence to support available satisfactory diagnostic 
instruments and treatment for Chlamydia.
2
 The sections below details the methods used for the 
literature search process.  
Literature Search Strategy 
An initial search was performed using PubMed-MEDLINE for systematic reviews (SR) 
and meta-analyses (MA) published from 2000 through September, 2010 and in the Cochrane 
Database of Systematic Review (CDSR) in September 2010 on screening for Chlamydia in men.  
Searches for articles specific to each KQ were conducted to supplement evidence found in the 
initial search.  SRs and Mas were reviewed at the abstract stage and the articles were reviewed 
for relevance to each key question and graded for quality.  
This review will focus on the evidence of the effectiveness of screening strategies in men, 
as well as evidence that screening and treating Chlamydia in men improves health outcomes in 
KQ1: Does screening for Chlamydia in men reduce morbidity in men or 
women? 
 
KQ2a: Does screening for chlamydial infection in men reduce the incidence 
of infection in men or women? 
 
KQ2b: Who should be screened? What are the risk factors for chlamydial 
infection in men? 
 
KQ3:  What are the adverse effects of screening for Chlamydia in men? 
 
KQ4:  What are the adverse effects of treatment for Chlamydia in men? 
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both men and women.  This review will also focus on the adverse effects of screening, as 
previous reviews found gaps in the evidence, limiting the ability of the Task Force to make 
recommendations for or against screening.  Inconvenience, social stigma of sexually transmitted 
diseases, partnership discord and exacerbation of domestic violence among partners, and concern 
related to testing errors were among the adverse effects explored in the literature.  In this report, 
screening is defined as testing performed on asymptomatic persons.  Universal screening means 
that everyone is tested, regardless of symptoms or risk factors.  Selective screening tests only 
individuals who meet specific criteria. 
Key Question 1 and 2 
After the initial search of SR and MA conducted, a literature search was performed for 
controlled trials of Chlamydia screening from 2000 through September 2010 in PubMed-
MEDLINE and the Cochrane Central Registry of Controlled Trials (CCRCT).  The Medical 
Subject Heading (MeSH terms) Chlamydia was combined with the terms screening and men.  
All search terms are listed in Appendix C.  In KQ 2, all abstracts found for KQ1 were reviewed 
for data on changes in disease frequency in the population. 
Key Question 3 
In addition to the initial search for SRs and Mas, all abstracts located for KQ1 and KQ2 
were reviewed for screening-associated harms.  An additional search on PubMed-MEDLINE 
was conducted from 2000 through September, 2010 to locate large observational studies 
addressing adverse effects by searching for publications that included terms to capture harms 
generally (adverse events, harms) and potential harms suggested earlier in the review 
(inconvenience, social stigma, etc.) without restrictions related to study design. 
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Key Question 4 
In addition to the initial search for SRs and Mas, all abstracts located for KQ1, KQ2, and 
KQ3 were reviewed for treatment-associated harms.  An additional search of PubMed-
MEDLINE from 2000 through September, 2010 was performed to locate large observational 
studies addressing adverse effects by searching for publications that included medication terms 
or discontinuation of medication without restrictions related to study design. 
Inclusion/Exclusion Criteria 
 
A set of inclusion and exclusion criteria was developed and applied generally, with 
specific additional criteria applied as needed to answer each key question.  See Appendix D for 
list of specific inclusion and exclusion criteria used for each KQ.  
Populations and Disorders 
The population of interest of this review includes sexually active men in the US, Canada, 
UK, Australia, New Zealand as well as other western European countries when data were not 
adequate for a specific key question.  While this review specifically focuses on Chlamydia, 
studies with other STDs were included if outcomes of diseases were measured separately.  
Studies with a primary focus on other sexually transmitted infections such as AIDS, syphilis, and 
gonococcal infections were not included.  Studies including only Chlamydia positive men 
(reinfected) or HIV positive men were also excluded as this review focuses on general screening 
programs for asymptomatic men in the population.  Studies of both men and women were also 
included if measured outcomes for screening men were found separately.  
Settings 
Primary care, emergency room, school based locations, STD clinic or other community 
practices and settings were included in this review. 
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Screening 
 Studies about screening programs were included if they provided descriptions of the 
study population, including number of men screened, age range, setting, and other important 
socioeconomic factors.  Screening program features such as time course of the study, type of 
testing, and type of test were also abstracted into evidence tables.  Studies were included if they 
use a recommended screening test, and screening trials must have used the screening results in 
the care of the intervention participants. 
Risk Factors 
Studies of risk factors for Chlamydia were included if they reported the number of men 
screened, age, setting, reason for visit, and other socioeconomic factors.  Screening criteria used, 
type of Chlamydia test, and prevalence rate of the tested population were abstracted into 
evidence tables.  
Treatments 
Studies that used the first line agents azithromycin and doxycycline were included if they 
were used in the treatment of Chlamydia such as from a positive test or urethritis.  Because we 
wanted to include all harms associated with treatment of Chlamydia, second line medications 
were included as well (tetracyclines, erythromycin, etc.).  However, treatment of complications 
such as epididymitis and proctitis were excluded.  
Outcomes 
 Outcomes of interest were changes in frequency of infection in the women or the total 
population.  Health outcomes of interest included: treatment of Chlamydia, changes in frequency 
of related sequelae, reinfection rates, quality of life ratings, change in sexual behavior practices, 
or change in health status.  KQ3 and KQ4 focused on harms associated with screening or 
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treatment including inconvenience, social stigma of sexually transmitted diseases, possible 
discord and exacerbation of domestic violence among sexual partners, and concern related to 
testing errors, serious medical events and discontinuation. 
Quality 
―Good‖ and ―fair‖ quality papers are included in this review.  Summaries of all papers, 
including ―poor‖ quality studies can be found in the abstractions tables (Appendix G). See 
section below for discussion of methodology of data abstraction and quality assessment. 
Date and Language 
 Only articles published in English between 2000 and September 2010 were included in 
literature search.  
Data Abstraction and Quality Assessment 
Only results pertaining to screening men were abstracted into tables, as programs that 
screen women only are out of scope with this paper. All resulting studies were reviewed and 
assessed for methodological quality. Adapted from the STROBE statement for reporting 
observational studies, a standardized abstraction form was used to critically appraise the quality 
of studies in regards to the following possible categories: (1) completeness of study description 
of intervention and comparison populations; (2) sampling method and potential for selection 
bias; (3) completeness of study intervention description; (4) validity and reliability of the 
measurement of exposure; (5) validity and reliability of the measurement outcome; (6) 
appropriate statistical analysis; (7) attrition, loss to follow-up; and (8) identification and 
discussion of potential biases and confounding, with or without analysis adjustments to 
control.
44,45
 The STROBE statement does not specify criteria for assessing quality of the study. 
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For the purposes of this review, quality of studies was determined by the number of limitations: 
good (0-2 limitations), fair (3-4 limitations), or poor (5-8) quality.   
Literature Synthesis 
Because of the diverse methodologies among reviewed studies, a qualitative synthesis of 
the literature is detailed in this review paper. A quantitative synthesis was not conducted, 
although data from published meta-analyses for KQ4 on the adverse effects of treatment was 
included.  For each Key Question, the results of the literature review are critically synthesized 
using papers of ―good‖ and ―fair‖ quality. 
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RESULTS 
Literature Review Process 
A total of 497 titles and abstracts were found from the initial search of databases and 4 
hand-selected articles from references of relevant articles (See Appendix E for search results and 
flow chart). After 165 duplicate articles or studies were removed, and remaining articles were 
sorted by titles and abstracts for relevance.  The full-text versions of the remaining 63 articles 
were skimmed for inclusion and exclusion criteria of the applicable key question(s).  The final 8 
articles that met all inclusion and exclusion criteria were then abstracted using the created table 
and rated for quality as detailed in the methodology section. Below are the results for each key 
question.  
Key Question 1: Does screening for Chlamydia in men reduce morbidity in men or women? 
 The literature search did not produce any new study published which used biological 
outcomes of morbidity or mortality of women and men when screening men for Chlamydia in 
the designated time period. 
Key Question 2a: Does screening for Chlamydia in men reduce the incidence of infection in 
men or women? 
Summary of findings 
 The literature search produced one ―fair‖ quality study that followed a screening program 
for male inmates and the effects of test positivity in women from the surrounding areas. Men 
incarcerated in the Philadelphia prison system have received systematic screening examinations 
for Chlamydia since 2002. Using ZIP codes of the prisoners to identify areas of ―high-treatment‖ 
versus ―low-treatment,‖ investigators were able to compare changes in test positivity of 
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neighborhood women during the two years before the start of the screening program and the 
three years after.   
Researchers found that both high-treatment and low-treatment areas had a decline in test 
positivity. In high-treatment areas, positivity significantly declined from 10.6% in 1999, 8.7% in 
2001 (p<0.05). In low-treatment areas, positivity decreased as well; 7.3% in 1999, 5.5 in 2001, 
and 4.2 in 2004 (p<0.05).  While these results are statistically significant decline in test positivity, 
the downward trend started even before the prison screening program was implemented. With 
numerous limitations in bias and confounding variables, investigators were not able to conclude 
that the decline in the rate of positivity in women was due to the prison screening program. 
Study Details (Appendix G, Table 1) 
Peterman 2009
46
 
 In a retrospective comparative study using data from the Philadelphia STD control 
program and Region III of the Infertility Prevention Project (IPP), investigators analyzed the 
influences of a male screening program on the rate of test positivity of women over a 5-year 
period to document rates 2 years before implementation of the program and 3 years after.  They 
collected test results from women 20 to 24 years-old, who tested in family planning clinics 
operated by IPP. This age group was selected because several other testing sites are available to 
women in Philadelphia, specifically high-school programs that are meant to target 15 to 19 year-
old women. Investigators have therefore excluded younger-aged women from the analysis to 
eliminate this confounding variable, which may give the appearance of a declining prevalence in 
the community. 
 Test results from the family planning clinics were categorized by geographic area using 
ZIP codes of residences for men treated for Chlamydia and released from prison. By using the 
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2000 Census for population estimates of 20 to 24 year old men in each ZIP code, investigators 
designated the highest 18 areas with a proportion of prisoners receiving treatment to compare 
with the lowest 18 areas of treatment.  In 2002 to 2004, 4263 positive Chlamydia tests were 
reported in Philadelphia for men aged 20 to 24, of which 34.7% of were diagnosed in the prison 
system. During that period, 1,054 prisoners of the high-treatment ZIP codes were identified, 
treated and released from jail. The high-treatment area had a populations of 23,203 men aged 20 
to 24, and a treatment rate of 1.5% each year. In low-treatment areas, 98 prisoners were treated 
in a population of 21,057, or 0.12% annually. 
 Researchers found that test positivity for women in the high-treatment areas decline over 
time from 10.6% in 1999, to 8.7% in 2001, and 7.4% in 2004 (p<0.05). The relative rate of 
annual decrease was greater even before implementation of the male prisoner screening program. 
Similarly, test positivity for women in the low-treatment areas declined over time from 7.3% in 
1999, to 5.4% in 2001, and 4.2% in 2004 (p<0.05).  
Key Question 2b: Who should be screened, and what are the risk factors for Chlamydia? 
Summary of findings 
The literature search resulted in four studies pertaining to risk factors and associations 
with Chlamydia testing positivity. The literature search produced one of ―good‖ quality, one 
―fair‖ quality, and two ―poor‖ quality studies that identified possible risk factors for Chlamydia 
positivity which could be used to improve effective detection of infection in men. 
A ―good‖ quality study of a comprehensive Chlamydia screening program in the UK 
included 97,121 men with an overall Chlamydia positivity rate of 7.6%. They found that men 
aged 19 to 24 experienced a rapid increase in risk as compared with 16 year-old adolescent men. 
Positivity was also higher in black men than white men, and when reporting a new partner in the 
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last 3 months, or having two or more partners in the last year. This study found there was slightly 
higher detection of Chlamydia in family planning centers, and lower positivity rates in hospitals. 
Otherwise, positivity rates were only slightly variable depending on screening setting. 
In a ―fair‖ quality study conducted in the U.S., investigators looked at positivity rates in 
adolescent men tested at school-based health centers. Using a self-administered questionnaire on 
sexual behaviors, data was collected to compare demographic characteristics and sexual health 
behaviors associated with Chlamydia positivity. The results show an overall prevalence of 6.8% 
positivity in 1,434 middle-school and high-school aged students from Baltimore and Denver. In 
the Denver cohort, condom use with their main (OR 0.30, 95% CI, 0.10, 0.91) or casual partner 
(OR 0.15, 95% CI, 0.03, 0.78) was protective against infection. In Baltimore, age was the only 
statistically significant risk associated with infection (OR 1.47, 95% CI, 1.23, 1.75). In 
multivariate analysis of several variable, age greater than 16 (AOR 1.34, 95% CI, 1.11, 1.62) and 
black race (AOR 2.37, 95% CI, 1.21, 4.63) were associated with testing positive. While there are 
limitations of self-reported data, under-reporting of negative sexual behaviors and over-reporting 
of condom use, suggest that there may be associations may be stronger than the results reflect. 
Study Details (Appendix G, Table 2) 
Simms 2009
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 The Health Protection Agency of the United Kingdom implemented the National 
Chlamydia Screening Program (NCSP) in 2003, which seeks to offer annual screening for all 
sexually active men and women under age 25. In 2007, with full participation of local primary 
care commissioners in England, this study was conducted to examine the variations of 
Chlamydia positivity throughout the country. 
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 For each of the 334,902 screening tests performed, of which 29% were men, multiple 
variables were collected, including gender, age, race, recent sexual partner history, and 
Chlamydia test result. They found and overall Chlamydia positivity of 7.6% in men. Using 16 
year old white males screened in general practice, multivariate analysis showed rapid increase in 
positivity with ages 19 [AOR: 2.58 (95% CI, 2.25, 2.94)] to 24 [AOR: 2.84 (95% CI, 2.49, 3.24)]. 
Risk of positivity was higher among young men of black Caribbean [AOR: 2.02 (95% CI, 1.79, 
2.27) and black background unspecified [AOR: 1.90 (95% CI, 1.61, 2.24)]. When compared with 
patients screened in the general practioner’s office, only screening test done at community 
contraception services and youth clinics had statistically significant higher positivity rates. 
Multivariate analysis showed that for men, risk of positivity increased significantly with age (P < 
0.0001), ethnicity (P < 0.0001), clinic setting (P < 0.0001), a new sexual partner in the past 3 
months (P < 0.0001), and reporting 2 or more sexual partners in the yea (P < 0.0001). 
Joffe 2008
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 In order to improve cost-effectiveness of Chlamydia programs targeted for men, a group 
of investigators studied risk and protective factors for asymptomatic men in schools or school-
based health centers (SBHC) in the Baltimore and Denver areas. From 1999 through 2003, they 
recruited high school and middle school children. In Baltimore, all men were enrolled with 
parental approval for complete well-adolescent examinations and were asked to complete the 
Guidelines for Adolescent Preventive Services (GAPS) questionnaire, which was developed by 
the Department of Adolescent Health of the American Medical Association
48
. The questionnaire 
covers a broad array of health behaviors topics, including sexual health. If the student indicated 
they were sexually active, a first-catch voided urine specimen was collected for Chlamydia and 
Gonorrhea testing. Sexually active men were also given a second questionnaire, the Baltimore 
24 
 
Region III chlamydia data form that included questions about symptoms, recent sexual activity, 
and condom use. Patients seeking care at the SBHCs for urogenital symptoms were excluded 
from the study. Recruitment methodology was different in Denver, in that men were not 
recruited during a wellness exam, but during acute care visits and sports physicals. 
 In Baltimore, 56% (n=1090) students accepted screening; in Denver, 17% (344) men 
accepted screening, for a total of 1,434 enrollees. Prevalence for chlamydia was 7.5% and 4.7% 
in Baltimore and Denver, respectively, with an overall prevalence rate of 6.8%.  Their study 
showed that in the Baltimore cohort, age greater than 16 was associated with an increased risk of 
chlamydia positivity [OR 1.47 (95% CI, 1.23, 1.75)]. In the Denver cohort, self-reported condom 
use with either the last main [OR 0.30 (95% CI, 0.10, 0.91)] or casual partner [OR 0.15 (95% CI, 
0.03, 0.78)] had protective associations. In multivariate analyses of both cities that included age, 
race, history of STI, sexual partner history and condom use, only age at 16 and older [AOR 1.34 
(95% CI, 1.11, 1.62)] and black race [AOR 2.37 (95% CI, 1.21, 4.63)] were associated with 
testing positive for chlamydia. No other variables were statistically significantly associated with 
chlamydia positivity. 
Key Question 3: What are the adverse effects of screening for Chlamydia in men? 
Summary of findings  
In weighing evidence for and against screening, known and potential harms must be 
considered. The most frequently discussed adverse effects of screening for Chlamydia are the 
psychological, emotional, and social impacts of receiving testing and receiving a positive 
diagnosis.  Known harms of screening include anxiety, both about the test and about potential 
results, stigmatization, fear of partner’s reaction, and fear of future fertility from a positive 
diagnosis. The literature search produced two good-to-fair studies examining the adverse effects 
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of screening men and women. One study conducted in the United Kingdom surveyed 842 
individuals aged 16-35 years old for anxiety, depression and self-esteem at three points in time: 
before screening, at screening, and after receiving a negative result. Though not statistically 
significantly different, the study found that women had generally higher levels of anxiety, 
depression, and lower self-esteem. Particularly, men’s anxiety levels decreased after screening, 
whereas women were only relieved after a negative result. Another cross-sectional study 
conducted in Denmark found that among 277 participants who received the screening test, 25.6% 
(n=71) were unaware that they could have Chlamydia and received screening test after being 
offered by the general practitioner. Of the 71 participants, 11.3% (n=8) felt stigmatized by being 
offered testing, while 82% (n=58) felt satisfied. Among infected individuals, 34% of sexual 
partners were upset by the diagnosis and 10% of relationships ended.  
Study Details (Appendix G, Table 3) 
Campbell 2006 
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In the 2006 article describing the ClaSS project, 842 individuals were randomly selected 
from a pool of 19,773 men and women registered in the National Health Service in the Bristol 
and Birmingham areas of the UK for an invitation for home-based screening for Chlamydia and 
for answering questionnaires to assess levels of anxiety, depression, and self-esteem at three time 
points: before the invitation for screening, at screening, and after a negative result. Using a fixed 
proportion randomization scheme, individuals were randomly selected to receive an invitation 
letter from their general practitioner followed by the study packet including information on how 
to provide home-collected urine sample and/or vulval swab sample. Initially designed as a 
prospective cohort study, the low response rates from the first four practices compelled 
investigators to select independent cross-sectional randomized samples of individual at each of 
26 
 
the three time points, stratified by sex and practice, as well as limiting the age bracket to 16-26 
year old. The main outcomes were assess by using the Hospital Anxiety and Depression Scale 
(HADS), a simple and reliable questionnaire and valid when used in community settings and 
primary care medical practice.
50
 The Rosendburg Self-Esteem Scale was also used to measure 
stigmatizing effects of screening for Chlamydia. In the analysis, the cohort and cross-sectional 
groups were combined after assessing similar response rates, similar outcomes after adjusting for 
age and sex. 
The investigators found that in general men reported experiencing less negative impacts 
of screening than women when considering all three time periods. While there was not 
statistically significant differences between genders, mean scores were 6.52 (SD = 3.60) and 6.27 
(SD = 3.38) for 16-25 year old and 26-39 year old men, respectively. Women had mean anxiety 
scores of 8.14 (SD = 3.89) and 8.28 (SD = 3.63) for the same age groups. Depression scores 
were lower in younger age groups, and lowest in men aged 16-25. Mean depression scores were 
3.01 (SD = 2.8) and 4.12 (SD = 3.6) for 16-25 year old and 26-39 year old men, respectively. 
Women had mean depression scores of 3.63 (SD = 3.2) and 4.42 (SD = 3.2) for the same age 
groups. Self-esteem was similar for age groups and sex, but was slightly lower in young women. 
The investigators also investigate changes in anxiety, depression, and self-esteem levels 
across time. They found statistically significant (p=0.0049) decreases in mean anxiety levels 
before, during (-0.66, 95% CI -1.23,-0.09), and after screening (-0.99, 95% CI -1.60,-0.38) and 
evidence that the pattern was different for men and women (p=0.012 for interaction). Men 
anxiety levels occurred after submitting their test sample, and women anxiety levels only 
decreased after receiving a negative result. There was no increase in anxiety as a result of 
receiving the invitation; however, this only captures individuals who responded to the 
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questionnaires. There was not a clear pattern of depression and self-esteem across the three time 
points. While depression was lower and self-esteem was higher after receiving a negative test 
results, findings are not significant and no clear interpretations can be concluded.  
While there were no significant differences between men and women overall, the results 
of this study show that large population-based screening for Chlamydia does not have deleterious 
impact on the psychological well-being of those tested. Having an invitation for screening and 
during screening did cause increases in anxiety and depression and decreases in self-esteem, but 
these were not lasting with relief with a negative result. In fact, sub-analyses showed that men 
were less negatively affected by screening, and psychological improvements were seen 
immediately after submitting testing samples.  
Kangas 2006 
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A cross-sectional survey of 277 men and women was conducted in Denmark to quantify 
potential psychosocial effects of testing for Chlamydia and receiving a positive or negative 
diagnosis. In Aarhus County, where the study was performed, 90% of Chlamydia tests are 
performed in general practices. Investigators recruited 91% of all the general practices in the 
county. Patients coming for a visit were recruited by their general practitioners by being asked if 
they would be screened for Chlamydia and mailed the survey within a week.  
The survey addresses three topics that were found to be areas of concern from the few 
studies on the psychological impacts of screening of women participants: the magnitude of 
stigmatization, partner’s reaction to positive diagnosis, and anxiety over future reproductive 
health. Participants were divided into two cohorts for analysis of outcome: the proportion of 
those with a positive diagnosis was compared with those with a negative diagnosis, and sub-
analysis was also performed for gender.  
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 A total of 277 (81.2%) individuals’ mailed responses were included in the study with 64 
individuals failing to respond after a reminder letter. Among these participants, 28 individuals 
were Chlamydia-infected men and 73 were non-infected men (n=101). When asked 
stigmatization of having a positive diagnosis, 50% of infected men and 56% of non-infected men 
felt it was a private matter and would not tell anyone (p=0.549). 46% of infected men and 18% 
of non-infected men felt they would be embarrassed to talk about testing with others. Concerning 
questions directed to their reaction to receiving test results, 14% of infected men were upset, 
21% felt despair, 29% felt embarrassed, and 32% felt no emotional impact. In contrast, non-
infected men were not upset (0%; p=0.007), 4% felt despair (p=0.022), 3 felt embarrassed 
(p<0.001), and 34% felt no emotional impact (p=0.708). On topics concerning psychosocial 
impacts in relation to their sexual partner among those with a positive diagnosis, 25% felt 
―dirty‖, 43% felt relieved, and 75% of partners were understanding. Among those with a 
negative diagnosis, none felt ―dirty‖ (p<0.001), 10% felt relieved (p=0.450), and equally 75% of 
partners were understanding (p=0.891). 83 of the 101 men tested had requested Chlamydia 
testing because of suspected exposure, exposed partner, previous infection, new partner, or 
others. The remaining 18 men were offered testing by the GP. Of these 18 men, 16 (88.9%) was 
satisfied with the offer, 1 (5.6%) felt stigmatized, and 1 (5.6%) felt no emotional impact.  
Key Question 4. What are the adverse effects of treatment for Chlamydia in men? 
Summary of findings 
 The literature search resulted in one good meta-analysis that reported overall efficacy 
rates and adverse effects of medication including discontinuation as the measures of impact of 
adverse effects associated with  antibacterial treatment of genital Chlamydia.
52,53
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Adverse effects associated with treatment for Chlamydia included tolerability of 
medication—typically diarrhea, abdominal pain, nausea, vomiting, dyspepsia, and constipation. 
53, 54
 Other adverse events examined were evidence of serious and rare medical events associated 
with the most common antibacterial agents doxycycline and azithromycin as well as less 
commonly prescribed antibacterial medications. 
Study Details (Appendix G, Table 4) 
Lau 2002 
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A meta-analysis of twelve randomized clinical trials evaluated the efficacy and tolerance 
of azithromycin and doxycycline for genital Chlamydia in 1542 patients for microbial cure of 
infection and 2171 patients for adverse events.  The review searched multiple databases from 
1975 to 2001 for randomized controlled trials of oral doxycycline and azithromycin in males 
aged >15 and nonpregnant females aged >15 with evaluation of microbial cure with CT 
biological assay negativity at a 2-5 week follow-up. 
In the azithromycin group, microbial cure occurred in 853 of 884 patients (96.5%) and in 
the doxycycline group, 645 of 659 (97.9). Adverse events were reported by 319 of 1274 (25.0%) 
azithromycin-treated patient and 205 of the 897 (22.9%) of the doxycycline-treated patients. The 
pooled efficacy difference between the two antimicrobial agents is 0.008 (95% CI, -0.007-0.022, 
p=0.296) and was not statistically significant. The pooled risk difference was also not 
statistically different at 0.009 (95% CI, -0.19-0.037, p=0.533). 
The most frequently reported adverse events were gastrointestinal in nature (87.3%) 
including diarrhea, abdominal pain, nausea, vomiting, dyspepsia, constipation, flatulence, and 
other unspecified symptoms. Other non-gastrointestinal symptoms included fatigue, malaise, 
sweating, dizziness, headache, skin rash, fever, and other unspecified symptoms. There were no 
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studies that looked at a study population of only men with Chlamydia. However, we can assume 
that biologically, men and non-pregnant women would have similar adverse effects—mostly 
typically mild GI symptoms. There were no major adverse events documented in the review, and 
both regimens of azithromycin and doxycycline were found to be equally safe and efficacious.  
There were some limitations on the quality of the review (limitations = 4, ―fair quality‖) 
that prevent broad generalization to the safety profile of azithromycin and doxycycline. The 
review does not discuss the characteristics or demographics of the populations studied in each of 
the trials. However, it is unlikely that differences in socioeconomic status and different provider 
care settings should affect biological harms of the antibiotic treatment received. Also, the review 
does not assess the method of recording adverse events used in the different studies. It is possible 
that come methodologies are less reliable than others, such as self-reported events versus a 
thorough interview by a health care provider or anonymous questionnaire.    
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DISCUSSION 
Screening men: Effects on Chlamydia burden in men and women 
 Despite efforts to decrease the burden of Chlamydia infection in women through national 
recommendations, the impact of screening programs for women alone has not been clear. 
Confounded by increased detection with increased screening, incidence of Chlamydia continues 
to rise with increased risk for reproductive complications. Screening of asymptomatic men is a 
strategic approach to detect, treat, and prevent the transmission of the STI. However, there is a 
paucity of studies that look at the effects of this disease control method on the changes in 
frequency in the population and no studies on changes in disease morbidity and mortality. 
 The literature produced only one study, which was of ―fair‖ quality, with inconclusive 
findings. By focusing on a small subsection of the prison-based screening in Philadelphia and its 
effects on women aged 20 to 24 seen in family planning clinics, there is a high degree of internal 
validity as well as generalizability to the broader population of Philadelphia and the rest of the 
U.S. Furthermore, there were issues in methodology and using ZIP codes to designate 
overlapping sexual networks between the prisoners and neighborhood women. Also, 20 to 24 
year old men may have been engaging in sexual relationships with younger-aged women who 
were excluded from the study. With too many unknown variables confounding the relationship 
between male screening and changes in positivity rates in women, the findings from this study 
are inconclusive. Screening men for Chlamydia remains difficult because asymptomatic men 
seek health care infrequently. Prison-based screening programs are a good potential to detect and 
treat latent infections, however the impact on disease prevalence is difficult to determine.  The 
lack in research and well-conducted studies that investigate the relationship between screening 
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men with biological outcomes in women preclude any determinations on the effectiveness of this 
disease prevention method.  
Risk Factor Identification 
Infected but asymptomatic young men are an elusive group to screen for STIs because 
they are not likely to seek medical care when feeling well, unlike their female counterparts who 
tend to have more regular visits for general reproductive health. Therefore, descriptive studies 
can guide screening programs for men in order to enhance cost-effectiveness, and efficiency in 
capturing positive cases.  
The English study on the NCSP dataset was based on one of the most comprehensive 
Chlamydia screening programs performed in the UK and was of ―good‖ quality. However, 
coverage of the target population was low (4.9%), and as a result, may not represent all young 
men at risk of Chlamydia infection. Because population prevalence could not be ascertained, 
positivity was appropriately used as the outcome measure, with 16 year-old white men as the 
referent group. The study found that positivity was significantly higher for men aged 19-24 and 
black Caribbean and unspecified black background. These findings indicate that screening 
programs must ensure that services are available not only to school-aged children, but target 
young adults as well. The high positivity rates may indicate high prevalence of Chlamydia in this 
study population. As only 29% of screening tests in the study were men, new strategies to 
increase participation must be implemented to ensure all men at risk receive equitable and 
accessible health services. 
Joffe et al. conducted a ―fair‖ quality study that looked at male students in the Baltimore 
and Denver areas. There were a few areas of concern in the methodology and analysis of the 
study. Because the two study populations of Baltimore and Denver were so different in 
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demographics, analysis was performed both separately and together. This may have weakened 
the power of the study, as the number of participants in Denver was low. Additionally, the study 
does not specify the conditions under which the questionnaires were administered. It is unlikely 
that responses remained anonymous, as it was also used as a tool by providers to discuss health 
concerns. This is concerning for the reliability of the responses used to analyze risk factors for 
Chlamydia. The self-reporting nature of their healthy behaviors may not accurately reflect true 
behavior. Students may be embarrassed and under-report poor sexual health habits and over-
report safe sexual practices. Because of this bias, associated risk and protective factors may be 
more strongly associated with STI positivity than the study reports. The overall positivity rate of 
6.8% among only asymptomatic men in this study indicate that SBHCs can be an appropriate 
health care setting, especially in high-prevalence areas, to identify and treat chlamydia infection 
in asymptomatic men. SBHCs can provide STI screening and counseling on sexual behavior at 
the start of sexual activity that is accessible without transportation, available at convenient hours, 
and at affordable costs. More school-based studies and analyses are needed to guide future 
screening recommendation for adolescent aged children. 
Adverse Effects of Screening  
 There is a paucity of studies that investigate the harms of screening men for chlamydia in 
large population-based screening programs. The literature review produced two cross-sectional 
survey studies of good and fair quality assessing the psychological impacts of screening both 
men and women that included analyses of men alone.  
The ClaSS study from the UK had moderate issues with selection bias and study design, 
but can still be considered a ―good‖ study. There is a moderate degree of selection bias of 
volunteering participants and results may reflect a population with less psychological morbidity. 
34 
 
It is quite possible that the non-responders have a different psychological profile, but this is 
difficult to assess.  Also, data on post-result levels of psychological distress, the survey only 
captures individuals with negative results. We can assume that anxiety, depression and low-self-
esteem will continue in those that have a positive result, but these patients will likely follow-up 
with their GPs, receive appropriate therapy and behavior counseling to reduce future risk of STI 
acquisition.  
The ClaSS study found that women experience anxiety, depression, and self-esteem more 
intensely than men, but not with statistical significant.  However, the ClaSS project did find that 
and increases in anxiety and depression and lower self-esteem experienced with an invitation for 
screening by the general practitioner decreases once the patient has undergone testing. This is 
different than women who experience continued distress until receiving a negative result. When 
screening for sexually transmitted infections there is always the potential for increasing 
psychological morbidity regardless of whether there are overall health benefits of screening. This 
study has policy implications to include men in screening for Chlamydia as part of large 
screening programs, as they do not seem to have serious injuries to their psychological health. 
As for the Danish study by Kangas, screening practices for Chlamydia are different in 
Denmark from that of the US. There are four clinical instances for individuals to receive testing: 
(1) patients are experiencing symptoms; (2) asymptomatic people with frequent sex partner 
change; (3) women under 26 before intrauterine device insertion or hysterosalpingogram; and (4) 
as part of the small opportunistic screening program.
54
 There is however no national screening 
program in place in Denmark. Rather only two communities receive annual chlamydia testing 
through pilot programs using register-based postal invitations.
55
 Also, the questionnaire used in 
the study was based on previously published qualitative studies on British women. Men and 
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women may think differently about these issues, as may the Danish and US population in general 
as well. However, this survey addresses the psychological stresses and anxieties of testing and 
can be applied to a broad population of sexually active youth.  
Considering the limitations of this article (4), this ―fair‖ study of both Chlamydia-positive 
and negative men have similar reactions to Chlamydia testing. However, men felt some degree of 
embarrassment and stigmatization, most men were satisfied with testing, and the majority of men 
felt to emotional impact from test answer, and felt relief. 
The findings from both these studies are consistent with similar small-scale surveys 
observed for other screening program, which suggest that individuals are unlikely to suffer 
profound or long-lasting emotional effects as a result of participating, and that the experience 
may even have a positive effect on their well-being. For example, a recent questionnaire-based 
survey of a random sample of men and women aged 15 to 29 who responded to an invitation for 
be screened for chlamydia by means of a home based urine sample in the Netherlands, found that 
42 % felt relief at receiving a negative result and that only a small minority of those receiving a 
negative result remained anxious.
56
  Also, men react differently than women, generally being less 
influenced by having a test offer and a positive or negative test result. Therefore, it is feasible to 
incorporate men in universal screening programs in a preventive strategy. However, conditions 
of anxiety, stigma, and depression, even if temporary, are important topics that require 
appropriate counseling by health care providers for both men and women. 
Adverse Effects of Treatment 
There was no randomized study found that directly compared the intensity and duration 
of adverse events associated with azithromycin and doxycycline. The single ―fair‖ meta-analysis 
by Lau, et al. concludes that the efficacy of doxycycline and azithromycin were equal and safe 
36 
 
for the treatment of Chlamydia in men and women.  Approximately 23-25% of patients report 
adverse events with each antibiotic, mostly gastrointestinal in nature including complaints such 
as diarrhea, abdominal pain, and nausea. 
For the purposes of assessing harms with treatment for Chlamydia, the investigators 
assumed that adverse events in males treated for chlamydial urethritis are comparable to those in 
males treated with the identical regimen for nongonococcal urethritis of any etiology. Given that 
urethritis is a local infection and the pharmacokinetics is unlikely to vary with different 
infectious etiologies of urethritis, this is a reasonable assumption. This allowed investigators to 
capture more data and possible rare negative events. Even so, both antibiotic regimens were 
found to be equally safe and efficacious. 
Under these controlled trials, estimates of therapy efficacy can be overestimations under 
close observation and optimal conditions. In actual practice, efficacy may be compromised by 
partial compliance, especially for doxycycline, which is a longer multi-dose regimen. The 
compliance of the patient and length of therapy must be considered when selecting an 
appropriate therapy for Chlamydia. Patients may be more likely to take azithromycin as 
prescribed as a one-time dose, versus doxycycline which is indicated twice a day for seven days 
and result in treatment failure. A physician might conclude that azithromycin is the treatment of 
choice. The cost differential between single-dose and multi-dose therapy makes the medication 
choice a central issue in the environment of limited resources, and a comprehensive cost-
effectiveness analysis should be performed and dose–response trials may also be needed to 
evaluate less complicated doxycycline regimens, which can increase its safety profile and its 
affordability. 
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CONCLUSION 
Like previous systematic reviews published on chlamydia screening in men, there 
continues to be a lack of evidence on the effectiveness at lowering disease mortality and 
morbidity in women.
1, 2
 Obviously, there is a need for more research and studies of well-
conducted randomized trials establishing a direct relationship between screening men and control 
of disease burden through decreased prevalence of Chlamydia cases, PID, and other related 
complications. Chlamydia infection is both a very treatable and preventable infectious disease, 
yet it persists in the population, particularly in the young and black populations, leading to 
unnecessary health risks and complications.  To complement recommended screening of young 
women, screening asymptomatic men is a logical strategy for the treatment of latent infections 
and to prevent transmission, reinfection between partners, and the development of complications. 
However, there is insufficient data available to recommend any screening strategies of 
asymptomatic men at this time. 
The studies reviewed in this paper reveal that the harms of screening and treatment are 
mainly mild psychological distress associated with testing. However, the relief of receiving 
confirmation of negative test or treatment for a latent infection exceeds the harms. Likewise, 
treatment for Chlamydia is affordable and accessible, safe and effective.  Further, it is important 
that any screening program is part of a larger control effort which includes education, counseling 
safe sexual behaviors, and promoting condom use. 
The high prevalence of Chlamydia in asymptomatic men suggests a role for a broad 
screening program. Future research must incorporate current knowledge of risk factors for a 
screening strategy that is efficient at capturing men who infrequently seek out medical care, and 
effective in actually reducing the burden of disease.  
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APPENDIX 
 
Appendix A. USPSTF Recommendations Grading Classification*
¥ 
Grade  Interpretation 
A 
Strongly recommends that clinicians provide [the service] to eligible patients. The USPSTF 
found good evidence that [the service] improves important health outcomes and concludes that 
benefits substantially outweigh harms. 
B 
Recommends that clinicians provide [this service] to eligible patients. The USPSTF found at 
least fair evidence that [the service] improves important health outcomes and concludes that 
benefits outweigh harms. 
C 
The USPSTF makes no recommendation for or against routine provision of [the service]. The 
USPSTF found at least fair evidence that [the service] can improve health outcomes but 
concludes that the balance of benefits and harms is too close to justify a general 
recommendation. 
D 
The USPSTF recommends against routinely providing [the service] to asymptomatic patients. 
The USPSTF found at least fair evidence that [the service] is ineffective or that harms outweigh 
benefits. 
I 
The USPSTF concludes that the evidence is insufficient to recommend for or against routinely 
providing [the service]. Evidence that the [service] is effective is lacking, of poor quality, or 
conflicting and the balance of benefits and harms cannot be determined. 
*U.S. Preventive Services Task Force Ratings: Grade Definitions. Guide to Clinical Preventive Services, Third 
Edition: Periodic Updates, 2000-2003. http://www.uspreventiveservicestaskforce.org/3rduspstf/ratings.htm 
¥
The USPSTF grades reflect the strength of evidence and magnitude of net benefit.  
 
 
 
 
 
Appendix B. Summary of Evidence Reviewed on Screening Men for Chlamydial Infection 
Variable Grade 
Evidence that screening reduces morbidity and mortality in men Poor 
Evidence that screening reduces disease frequency in men and women Poor 
Evidence of identifiable risk factors to create targeted screening programs for men Good 
Harms of screening Fair 
Harms of treatment Fair 
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Appendix C. Search Strategies 
Table 1. Systematic Review on PubMed-MEDLINE 
Systematic Review 
Databases: PubMed-MEDLINE 
Limits: Dates: 2000 to September 2010, English language 
1 chlamydia/dt OR chlamydia/pc OR chlamydia/th 
2 Chlamydia* 
3 screen* 
4 #2 AND #3 
5 #1 OR #4 
6 Men OR male 
7 #5 AND #6 
8 #7 AND systematic[sb] 
 
 
 
Table 2. Systematic Review on Cochrane Database of Systematic Reviews 
Systematic Review 
Databases: Cochrane Database of Systematic Reviews 
Limits: Dates: 2000 to 2010 
1 Chlamydia* 
2 screen* 
3 Men OR male 
4 #1 AND #2 AND #3 
 
 
 
Table 3. Screening Trials 
Screening Trials 
Database: PubMed-MEDLINE, Cochrane Central Register of Controlled Trials 
Limits: Dates: 2000 to September 2010, English language, Clinical trials and RCTs 
1 Chlamydia* 
2 (Men OR male) 
3 Screen*[TIAB] / screen*:ti,ab (Cochrane) 
4 #1 AND #2 AND #3 
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Table 4. Screening Harms 
Screening Harms 
Database: PubMed-MEDLINE, Cochrane Database 
Limits: Dates: 2000 to September 2010, English language 
1 Chlamydia* 
2 Screen* 
3 Case finding 
4 casefinding 
5 #2 OR #3 OR #4 
6 #1 AND #5 
7 Men OR male 
8 #6 AND #7 
9 Adverse* 
10 Harm* 
11 Label* 
12 Stigma* 
13 Violen* 
14 #9 OR #10 OR #11 OR #12 OR #13 
15 #8 AND #14 
 
 
 
 
Table 5. Treatment Harms 
Observational Studies of Treatment Harms 
Database:  PubMed-MEDLINE, Cochrane Database 
Limits: Dates: 2000 October 2010, English language 
1 Chlamydia* 
2 Treatment 
3 Antibact* OR antibiotic* 
4 (#1 AND #2) OR (#1 AND #3) 
5 Men OR male 
6 #4 AND #5 
7 Advers* 
8 Harm* 
9 Discontinu* 
10 #7 OR #8 OR #9 
11 #6 AND #10 
 
 
 
 
 
 
 
41 
 
Appendix D. Inclusion and Exclusion Criteria for Key Questions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key Question 1 and 2: Screening Trials and Morbidity or Prevalence 
Inclusion Criteria 
1. Screening: study of Chlamydia screening in men; outcomes same as listed above. 
Exclusion Criteria 
1. Does not meet quality criteria. 
2. None of the outcomes listed above. 
3. Focus on women or pregnancy-related screening. 
4. Does not meet any inclusion criterion. 
5. Not a general primary care population. 
6. Not English language or non-developed country. 
7. Non-comparative study/excluded design. 
8. Pure comparative-effectiveness study. 
9. Screen not used in clinical care. 
10. Pure modeling study. 
 
Key Question 3: Screening Harms 
Inclusion Criteria 
1. Study addressing adverse events associated with Chlamydia screening in men. 
Exclusion Criteria 
1. Does not meet quality criteria. 
2. Focus on pregnancy-related screening. 
3. Does not meet any inclusion criterion. 
4. Not generalizable to primary care population 
5. Not English language or non-developed country 
 
Key Question 4: Treatment Harms 
Inclusion Criteria 
1. Systematic review, large cohort, or large prospective observational study addressing 
adverse events associated with Chlamydia treatment or screening in men. 
Exclusion Criteria 
1. Focus on inpatient, prison, MSM community, or other high risk group 
2. Focus on interventions other than antibiotics. 
3. Does not meet quality criteria 
4. None of the adverse effects of interest to our review above. 
5. Focus on pregnancy-related screening. 
6. Does not meet any inclusion criterion. 
7. Not a general primary care population 
8. Not English language or non-developed country 
9. Not a study design specified above. 
10. Comparative-effectiveness study. 
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Appendix E. Standardized Abstraction Table 
Study Reference Author, year 
Study Design RCT, descriptive studies, etc. 
Source and study 
Population* 
N. Age, sex, race/ethnicity, SES, and other description of demographics. 
Eligibility criteria? How were they recruited? Well described? 
Sampling* (and 
allocation if 
appropriate) 
Selection bias? Control group? Initial comparability of groups? 
Randomization process? Concealment of allocation? Representative? 
External validity? 
Missing data* Drop outs, adherence, crossovers, attrition, loss to follow-up. Alternative 
analysis? 
Intervention* Diagnostic test? Time period? Well described? 
Measurement of 
exposure* 
Potential confounding? Reliable and valid measurement instruments? 
Training or blinding? Reliable, valid, and equal? Time period? 
Measurement of 
outcome* 
Potential confounding? Reliable and valid measurement instruments? 
Training or blinding? Reliable, valid, and equal? Time period? 
Analysis* Intent to treat? Power analysis, control for design effects? Appropriate data 
analysis? 
Results Primary outcome measurement with confidence intervals, statistical 
significance 
Bias and 
Confounding* 
Possible confounding and biases identified and discussed? Any adjustments? 
Limitations Summary and score 0-8 
Overall quality Good = 0-2, Fair = 3-4, Poor 5-8 
*Categories used to assess study quality and limitations for grading 
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Appendix F. Search results and article flow  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
150 articles reviewed by 
abstract 
497 Found from search 
4 Hand selected 
501 articles 
336 articles reviewed by 
title 
165 duplicate articles or 
studies 
186 removed for 
irrelevance by title 
63 articles read 
87 removed for 
irrelevance by abstract 
8 articles abstracted and 
assessed for quality 
51 excluded based on 
criteria 
6 studies included in 
review 
2 excluded based on poor 
quality 
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Appendix G. Evidence Tables 
Table 1. Summary of articles on screening for Chlamydia in men to reduce incidence in men or women (Key Question 2a) 
Study 
Reference 
Study Design  Source Population Study Population Missing Data Selection Bias Intervention 
 
Peterman et 
al. 2009 
 
Question: Does 
a screening 
program 
targeting men 
influence test 
positivity of CT 
infection in 
women from 
neighboring 
areas? 
 
Design:  
Retrospective 
study cross-
sectional 
comparison 
 
Philadelphia population 
is about 1.5 million in 
2000. 
 
Investigators wanted to 
study the effects of CT 
testing and treatment of 
men on the prevalence of 
women in the same 
geographic area of 
Philadelphia. 
 
Investigators divided city 
into areas based on 
percent of men 
diagnosed and treated for 
CT via the prison 
screening program.  
 
 
Women 20 to 24 years 
old receiving CT 
testing at 56 family 
planning clinic sites in 
Philadelphia. 
 
70,309 tests in the area 
reported for a 
population of 62,657 
women.  
5664 (8.1%) cases of 
CT reported. 
 
No other demographic 
information given.  
 
Loss to attrition 
and follow-up does 
not apply to this 
study. 
 
ZIP codes were 
largely 
undocumented for 
CT negative 
inmates. Therefore, 
it is difficult to 
assess any 
geographic 
distribution or 
high-prevalence 
and low-prevalence 
areas. This was 
excluded from the 
study. Instead 
investigators 
compared high-
treatment and low-
treatment areas. 
 
First, this study has 
excluded younger 
women from the study 
to adjust for testing in 
other centers. However, 
most CT infection in 
women are in younger 
ages, so any effect will 
be smaller in the 20 to 
24 age group 
 
Second, because this 
intervention of male 
screening was 
performed in prison, it 
is difficult to assess the 
relationship they have 
with 20 to 24 year old 
women being seen in 
family planning clinics  
 
 
 
Philadelphia prison/jail 
chlamydia screening 
program. 
 
Average of 30,000 
prisoners released yearly 
from Philadelphia prison 
system from 1996 to 
2003.  
86% are men 
30% are18 to 24 years 
old 
70% black 
20% white 
10% Hispanic 
 
Most common reason for 
incarceration is ―pre-trial 
hold‖ (n=19,098 in 2003) 
for a median of 17 days.  
 
91% of identified CT 
among 20 to 24 year olds 
was successfully treated 
with single dose of 
Azithromycin (1g) or 7 
day course of 
doxycycline (100mg 
twice a day) 
 
CT=C.trachomatis (cont.) 
 
 
 
45 
 
Table 1. Summary of articles on screening for Chlamydia in men to reduce incidence in men or women (cont.) 
Study 
Reference 
Measurement of 
exposure/outcome 
Bias and 
Confounding 
Analysis Results Limitations 
Overall 
quality 
Peterman et 
al. 2009 
Change in test positivity for 
CT among 20 to 24 year 
old women 
 
Philadelphia receives 
federal funding from IPP 
for CT testing. Since 1995, 
policy was to screen all 
women <30 who attend 
family planning clinics and 
all women <35 who attend 
STD clinics. 
 
Starting in 1997, all CT 
testing was done using 
NAAT technology 
 
Geographic areas were 
defined using ZIP codes for 
men testing positive in 
prison. The 2000 census 
was used to estimate the 
number of men and women 
living in ZIP codes, which 
was then used to estimate 
the proportion of men 
treated for CT in prison for 
each ZIP code.  
 
A total of 47 ZIP codes 
were ranked for proportion 
of CT treated in prison. The 
18 highest treated areas 
were compared with the 18 
lowest. The middle 11 were 
excluded as it was used to 
develop analytic approach.  
Women testing at 
family clinic sites are 
only a small proportion 
of women at risk for CT 
infection. With a small 
sample, shifts in family 
practice year-to-year 
can cause significant 
changes in rate 
positivity. For example, 
testing can also 
performed in juvenile 
detention facilities, 
adult prisons, public 
school, and family 
court. The article has 
attempted to adjust for 
these other screening 
programs and have 
excluded women 15-19 
who may be receiving 
CT testing in school.  
 
Also, impossible to 
assume partnerships 
with women of 
community and men 
released from prison. 
We know 34.7% of all 
CT infections in men 
from 2002 to 2004 were 
diagnosed in the prison 
system; women may be 
getting infected from 
other sources. 
15 to 19 year old 
women were 
excluded from the 
analysis to address 
possible 
confounding in 
findings of 
prevalence. 
Because 16-19 year 
old can be tested in 
other sites like 
schools and not 
family planning 
clinics, results may 
give appearance of 
a false decline in 
community 
prevalence.  
 
 
70,281 tests in Philadelphia prison among 
all men: 
 16,860 in 2002 
 27,721 in 2003 
 25,700 in 2004 
 
4263 total positive cases among 20 to 24 
year old men in 3 years   
 1479 (34.7%) were diagnosed in prison 
 
23,203 men aged 20 to 24 in 18 highest-
treated ZIP codes 
1054 prison-diagnosed cases were treated in 
this area 
 
21,057 men aged 20 to 24 in 18 lowest-
treated ZIP codes 
98 prison-diagnosed cases were treated in 
this area 
 
In 1994 to 2004, 70,309 tests performed for 
women 20 to 24 in family clinics of 
Philadelphia 
 
No significant change of number of tests 
done in family planning clinic year-to-year, 
no apparent shift in testing from one ZIP 
code to another 
 
Test positivity in high-treatment areas: 
10.6% in 1999 
8.7% in 2001 
7.4% in 2004 
 
Test positivity in low-treatment areas: 
7.3% in 1999 
5.4% in 2001 
4.2% in 2004 
 
3: 
 
Source and study 
population. There was 
no description of 
demographics: age, 
race/ethnicity, or SES. 
No description of 
recruitment or any 
other characteristics 
 
Sampling. With 20-24 
year old females who 
are seen in family 
practice clinics, very 
limited selection of 
population for study. 
Also, with no 
description of sample 
population year-to-
year, difficult to assess 
comparability of 
cohorts 
 
Bias and confounding. 
Some sources of 
confounding addressed 
in paper, and adjusted 
in analysis. However, 
still high potential for 
selection bias, and 
confounding variables 
remain concerning 
sexual relationships 
between inmates and 
women  seen in clinic 
 
 
Fair 
CT=C.trachomatis 
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Table 2. Summary of articles for risk factors associated with Chlamydia positivity (Key Question 2b) 
Study 
Reference 
Study Design  Source Population Study Population 
Missing 
Data 
Selection Bias Intervention 
 
Simms, I et al. 
2000 
 
Question: What 
are the positivity 
rates of 
Chlamydia by 
different 
variables? 
 
Design: 
Retrospective 
prevalence study 
of national 
database 
 
Men and women 
under 25 who live in 
England (5.3 million 
people) 
 
Program criteria: 
Opportunistic testing 
for sexually active 
under 25 
 
Asymptomatic, 
without genital 
symptoms 
 
 
 
 
 
370,012 total screening tests 
 11,564 excluded for 
missing gender or test 
result 
 23,546 ineligible age 
(>25) 
 
334,902 tests available for 
analysis 
 29%  men 
 
Data was 
excluded if 
gender data 
was missing. 
 
NCSP is a national 
program managed at 
the local level. 
 
Per NCSP protocol, 
tests are offered at 
every opportunity, 
including routine 
medical follow-ups and 
other acute care visit 
 
Depending on location, 
various practices may 
more aggressively 
offer CT testing, 
causing regional 
differences in CT 
testing and positivity.  
 
Also, acceptance rates 
are low, especially for 
men. Some potential 
for confounding, and is 
difficult to ascertain 
prevalence of 
population.  
 
 
NAAT testing for CT 
in urine 
 
For each screening test, 
12 variables were 
collected, which 
included geographic 
location, 
demographics, sexual 
partner history, and test 
results.  
 
Sexual history is taken, 
and patients are 
advised of full STI 
screen, and safe sexual 
practices are advised.  
NCSP=National Chlamydia Screening Programme, NAAT=nucleic acid amplification test, CT = C.trachomatis                                                          (cont.) 
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Table 2. Summary of articles for risk factors associated with Chlamydia positivity (cont.) 
Study 
Reference 
Measurement of 
exposure/outcome 
Bias and 
Confounding 
Analysis Results Limitations 
Overall 
quality 
 
Simms, I 
et al. 2000 
 
Laboratories are 
certified under 
standard NCSP 
protocol. 
 
Per NCSP protocol, 
staffs are trained 
regularly and 
refreshed by local 
commissioners. 
 
  
 
Some concern for 
self-selection, as 
this is voluntary 
program. Those 
with higher 
perceived risks 
will more likely 
seek care. 
 
Also, there are 
varying patterns of 
testing by location. 
Some health 
settings screen 
more aggressively 
than others, and 
could result in 
lower positivity 
rates. 
 
Also, because of 
infectious nature 
of CT, can have 
higher prevalence 
areas that can 
confound risk 
factors for 
positivity.  
 
Because of large, 
nationalized scale 
of study, bias and 
confounding are 
only a moderate 
concern. 
 
Variables included 
for analysis: age, 
gender, ethnicity, 
new sex partner in 
last 3 mo, >2 
partners in 1 yr. 
 
Variation in 
positivity by location 
was explored using 
funnel plots.  
 
Means calculated and 
2-sided standard 
errors used to 
distinguish 
statistically 
significant variables.  
 
Univariate and 
multivariate logistic 
regression used to 
explore risk 
associations (OR) 
 
Men and women 
were analyzed 
separately. 
 
Stata 8.2 
 
 
Overall positivity in men was 7.6% 
 
Age: 16 as referent group. AOR (95% CI) 
 17: 1.55(1.38, 1.74) 
 18: 2.39 (2.14, 2.67) 
 19: 2.93 (2.62, 3.28) 
 20: 3.09 (2.76, 3.46) 
 21: 3.04 (2.69, 3.42) 
 22: 3.28 (2.90, 3.70) 
 23: 2.96 (2.60, 3.36) 
 24: 2.84 (2.49, 3.24) 
 
Race: White as referent. AOR (95% CI) 
 Black Caribbean: 2.02 (1.79, 2.27) 
 Black African: 1.30 (1.13, 1.50) 
 Black unspecified: 1.90 (1.61, 
2.24) 
 
Test Setting: GP referent. AOR (95% CI) 
 STI clinic: 1.09 (0.99, 1.21) 
 Hospital: 0.59 (0.53, 0.66) 
 Family Planning: 1.47 (1.34, 1.60) 
 Military: 0.71 (0.63, 0.81) 
 Prison: 1.09 (0.98, 1.22) 
 
New Partner in past 3 mo: NO is referent 
 Yes: 1.19 (1.11, 1.28) 
 
>2 partners in 1 yr: NO is referent 
 Yes: 1.66 (1.53, 1.79) 
 
 
 
1: 
 
Measurement of 
exposure: 
While there is strict 
protocol for offering 
testing eliciting sexual 
history, there was wide 
variation between 
geographic locations 
and types of health 
clinics.  
However, there was 
appropriate analysis 
using funnel plot to 
identify outlying areas. 
Location was among 
the adjusted variables 
in multivariate analysis. 
 
 
 
Good 
NCSP=National Chlamydia Screening Programme, CT=C.trachomatis, OR=odds ratio, AOR=adjusted odds ratio, CI=confidence interval, * p<0.05  
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Table 2. Summary of articles for risk factors associated with Chlamydia positivity (cont.) 
Study 
Reference 
Study 
Design 
 Source 
Population 
Study Population 
Missing 
Data 
Selection Bias Intervention 
Measurement of 
exposure/outcome 
 
Joffee, A et 
al. 2008 
 
Question: 
What are the 
risk factors for 
Chlamydia in 
school-aged 
children to 
increase 
benefit and 
cost-
effectiveness 
of screening 
programs? 
 
Design: 
multicenter 
targeted 
screening 
project for 
prevalence 
and risk 
factors 
 
Number of 
sexually active 
(eligible) students 
was not measured 
due to 
infeasibility.  
 
Eligibility criteria: 
any man attending 
high school or 
middle school 
with a SBHC 
 
Enrolled Oct 
1999-Jan 2003 
 
In Baltimore, only 
males seeking a 
complete wellness 
appointment and 
with parental 
consent for 
comprehensive 
care were asked to 
participate 
 
In Denver, men 
who presented to 
SBHC any 
reasons, including 
acute care and 
sports physicals, 
with the exception 
of urogential 
symptoms were 
recruited. 
 
1434 men attending a SCHC 
in high school or middle 
school 
 344 males from Denver 
(from 6 middle and 8 
high schools) 
 1090 males from 
Baltimore (7 high 
school-only SBHCs) 
 
11-21 years in age 
 
Two study arms are not 
comparable—Baltimore has 
an older group, recruiting 
only high-school aged 
males, being seen as part of 
a wellness examination 
 
In Denver, both middle 
school and high schools 
were included. Men were 
recruited during acute care 
visits and other visits, not 
including urogenital 
infections (ie sports 
physicals) 
 
Men were excluded from the 
study if they indicated 
symptoms of STD infections 
at time of screening, those 
who specifically sought STI 
services, or those who were 
referred by disease 
intervention specialist. 
 
 
No 
discussion 
of missing 
data. 
 
Moderate. 
 
Participation 
requires enrollment 
in school with 
SBHC and parental 
consent. Students 
are more likely to 
be educated with 
parents concerned 
in their health.  
 
Self-selected 
participation for 
screening. 
Especially in 
Denver, acceptance 
rates are low, but 
they were recruiting 
during acute cases 
(respiratory illness, 
sports injuries, etc.) 
 
In Baltimore, males 
completed the 
Guidelines for 
Adolescent 
Preventive Services 
(GAPS) 
questionnaire. For a 
general healthy 
behaviors, 
including sexual 
behaviors 
including: 
 Current 
symptoms, 
number of 
sexual partners, 
new partners, 
condom use, 
etc. 
 
If sexually active, 
were asked to 
provide first-catch 
voided urine 
specimen for CT 
and NG testing 
 
In Denver, men 
were given GAPS 
questionnaires by 
clinician. Sexually 
active men were 
offered screening 
tests for CT.  
 
Participants were given GAPS 
questionnaire which covers 
health behaviors, including 
sexual behaviors.  
 
Additionally, a second 
questionnaire, the Baltimore 
Region III chlamydia data form 
was administered in Baltimore, 
which covers current symptoms, 
recent sexual activity, number of 
sexual partners, and condom use 
with main and casual sex 
partners.  
 
There may be error in 
measurement due to self-
reporting nature of questionnaire 
format. Participants may be less 
likely to report unhealthy 
behaviors, biasing towards null. 
 
Patients provide 20mL of first-
catch clean urine for CT and NG 
testing by NAATs, both LCR 
and PCR were used with no 
statistically significant difference 
in sensitivities and specificity. 
 
Urine was processed and tested 
at approved and certified 
laboratories at local sites. 
Results were entered into 
database, and results sent to 
clinic for follow-up if required 
SBHC=school based health clinic, CT=C.trachomatis, NG=N.gonorrhea                                                              (cont.) 
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Table 2. Summary of articles for risk factors associated with Chlamydia positivity (cont.) 
Study 
Reference 
Bias and 
Confounding 
Analysis Results Limitations 
Overall 
quality 
 
Joffee, A et 
al. 2008 
 
Before implementation 
of study, SBHCs did 
not offer urine based-
screening for CT to 
asymptomatic men 
because of lack of 
funds. Relatively new 
strategy, so may have 
increase in errors. 
 
SBHC STI screening 
programs can only 
catch individuals who 
are attending school 
and who have parental 
consent for health 
services. However, 
prevalence of 6.8% CT 
in asymptomatic 
cohorts show SBHC 
can still be a useful 
venue to capture young 
men who would not 
otherwise seek health 
care. 
 
 
 
 
 
Analysis was performed with 
SAS 9.1 
 
Descriptive statistics and 
prevalence were conducted for 
all men together and separately 
for Baltimore and Denver 
cohorts. 
 
OR and 95% CIs were 
calculated for all men and 
separately for location. 
 
Univariate and multivariate 
analyses were performed for 
demographics and behavioral 
variables between men testing 
positively and negatively for CT 
 Variables significant to 
0.10 level in univariate 
analysis was entered in 
multivariate analysis 
 
Risk factor analysis was 
conducted for all men and 
separately for location to 
account for significant variables 
between the men from two cities 
 
 
 
Screening acceptance rate: 
 56% in Baltimore 
 17% in Denver 
 
CT prevalence: 
 7.5% in Baltimore 
 4.7% in Denver 
 6.8% overall 
 
Risk Factors [OR (95% CI)]: 
Baltimore 
Age >16: 1.47 (1.23, 1.75)* 
Black race:1.46 (0.58, 3.70) 
Prior STI: 1.49 (0.57, 3.88) 
Sex partner in 2 mo:1.56 (0.86, 2.85) 
>1 sex partner in 1yr: 1.39 (0.85, 2.28) 
Condom with main partner: 0.76 (0.42, 1.35) 
Condom with casual partner: 0.79 (0.36, 1.73) 
 
Denver 
Age >16:1.37 (0.94, 2.0) 
Black race: 1.39 (0.49, 3.92) 
Prior STI: 3.01 (0.62, 14.5) 
Sex partner in 2 mo: 1.17 (0.33, 4.23) 
>1 sex partner in 1yr: 2.03 (0.69, 5.98) 
Condom with main partner: 0.30 (0.10, 0.91)* 
Condom with casual partner: 0.15 (0.03, 
0.78)* 
 
Combined Adjusted OR 
Age >16:1.34 (1.11, 1.62)* 
Black Race: 2.37 (1.21, 4.63)* 
 
 
3: 
 
Sampling and selection bias. 
With any targeted program, there 
is some loss of capturing all 
infections in community. While 
this program does identify young 
men with CT, it is still in the 
scope of school based health 
centers and still requires parental 
consent. Further, only 17% of 
students in Denver accepted 
study participation. Along with 
los sample size and low power, 
there is additional confounding 
factors that warrants more 
research to increase participation 
in future screening programs.  
 
Measurement of exposure: 
Some questions in training, as the 
protocol is newly implemented. 
Also, no mention of blinding or 
anonymity for participant 
privacy. Potential confounding 
and bias towards null. May 
underestimate protective and risk 
factors  
 
(1/2) Missing data 
No discussion of missing data.  
 
(1/2) No discussion of bias and 
confounding factors in study 
results.  
 
 
 
Fair 
SBHC=school based health clinic, CT=C.trachomatis, NG=N.gonorrhea, NAAT=nucleic acid amplification testing, OR=odds ratio, CI=confidence interval, * p<0.05  
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Table 2. Summary of articles for risk factors associated with Chlamydia positivity (cont.) 
Study 
Reference 
Study Design  Source Population Study Population 
Missing 
Data 
Selection Bias Intervention 
Hiltunen-Back 
et al. 2001 
Question: Are 
there identifiable 
patient profiles 
of chlamydia 
positive 
individuals to 
improve 
preventive 
strategies? 
 
Design: Cross-
sectional study 
of database using 
Sentinel 
Surveillance 
Network of 
STDs established 
in 1995 
Multicenter study in 
Finland 
 
12 STD clinics and 
non-STD clinics 
comprising the 
Sentinel STD 
Surveillance 
Network: 5 STD 
clinics, 2 university 
student health 
clinics, 3 general 
practices, and 2 
gynecological clinics 
 
 
 
 
50,976 patients received 
screening in Sentinel STD 
Network Clinics in Finland from 
1995-1997. 
 
 32,230 patients were tested 
for Chlamydia in STD 
clinics 
 
 18,746 patients were tested 
for Chlamydia in non-STD 
clinics 
 
Unclear if this is part of a larger 
national healthcare system where 
all Finnish individuals have 
equal access. 
 
97% 
acceptance 
of 
questionnaire 
reflects high 
participation. 
Loss to 
follow-up or 
attrition rates 
does not 
apply. 
 
However, 
does not 
mention 
missing data 
No appointment and no 
payment necessary for 
clinic visits.  
 
Must be university 
student to utilize 
student clinic. 
 
Referral and payment 
is necessary to be seen 
at women’s clinic – 
due to high potential 
for selection bias, data 
from women’s clinic is 
excluded from study 
analysis 
 
In non-STD clinics, 
questionnaires only 
given to CT positive 
patients  
 
Some question of 
external validity as this 
population is Finnish, 
with different medical 
care system. However, 
as a Western European 
country as well as US, 
CT continues to be 
public health challenge 
with sustained 
incidence rates when 
other STD have 
decreased or remained 
low. 
Self-administered 
anonymous 
questionnaire with 21 
points 
 
Questionnaire includes 
demographic data (age, 
gender, occupation, 
nationality, place of 
residence), reason for 
visit, symptoms, and 
screening by patient’s, 
partner’s, or 
physician’s suggestion. 
 
Questionnaire also 
included time and 
place of exposure, 
course partner if 
known and notified, 
and history of sexual 
partners, and 
participation of other 
risky sexual behaviors 
 
A physician performed 
physical. Samples for 
CT, GC, Syphilis, and 
HIV were routinely 
taken. Urine sample 
was cultured (1995) in 
McCoy cells or 
immunoassays and 
PCR/LCR (after 1995). 
 
CT=C.trachomatis, GC=N.gonorrhea (cont.) 
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Table 2. Summary of articles for risk factors associated with Chlamydia positivity (cont.) 
Study 
Reference 
Measurement of 
exposure/outcome 
Bias and 
Confounding 
Analysis Results Limitations 
Overall 
quality 
Hiltunen-
Back et al. 
2001 
All patients receiving 
care at STD clinics 
received 
questionnaire. 97% 
agreed 
 
In non STD clinics, 
only patients positive 
for Chlamydia, 
Gonorrhea, Syphilis, 
or HIV infection were 
asked to complete 
questionnaire 
 
All questionnaire 
forms were 
anonymous and 
available in Swedish 
and English. Trained 
nurses were available 
for interpretation. 
These efforts 
minimize variability 
in intervention 
delivery. Also reliable 
and valid responses 
more likely. 
 
Data was entered by 
all 12 clinics using 
same software 
Fairly broad 
locations, free 
appointments 
and care. 
Again, some 
concern for 
external 
validity. 
 
Anonymous 
questionnaires 
with trained 
interpreters. All 
locations had 
same protocol.  
Patient data from STD 
and non-STD clinics were 
compared and those 
testing positive and those 
testing negative for 
Chlamydia. 
 
Analyses were performed 
for data collected over 
entire 3 year period. 
Initial subgroup analysis 
comparing 1995 and 1997 
year showed same risk 
factor result.  
 
Variables with normal 
distributions were 
described with means and 
standard deviations. 
Statistical comparisons 
for groups were 
performed by t-test, z 
test, and analysis of 
variance. Ordinal variable 
were described with 
median and interquartile 
range and were compared 
using Mann-Whitney test 
of Kruskal-Wallis test. 
Measures with discrete 
variables were expressed 
as percentages and 
analyze by chi-square 
test. 
3,686 had a positive 
Chlamydia test. 
 
8.4% overall positivity rate 
8.8% in men, 7.8% in 
women 
 
Age (mean, 95%CI) 
CT positive: 26.6 (25.9-
27.3) 
CT negative: 31.7 (31.3-
32.0) 
 
Prevalence in age group: 
15 to 19: 14.3% 
20 to 24: 13.6% 
25 to 29: 10.8% 
 
Infection source partner: 
Casual partner: 60.9%, 95% 
CI 58.4, 63.4 
Regular partner: 36.8%, 
95% CI 34.4-39.2 
 
 
 
5: 
 
Sampling/Source and study 
population 
Reliable internal validity of study. 
However, some questions with 
external validity remain. While a 
Western European nation with 
continuously high rates of CT, 
health system and social system of 
Finland is different from that of 
USA. It is likely a more 
homogenous group with access to 
free healthcare. Results reported 
from this study however are still 
valid and provide insights on key 
strategies for Chlamydia 
prevention. Additionally, unclear of 
recruitment and screening protocol 
of non-STD clinics. 
 
Measurement 
bias/Confounding/Analysis 
Because only CT positive patients 
received the questionnaire at the 
non-STD clinics, Chlamydia 
negative patients are only pooled 
from STD clinics. Two groups were 
not compared, and analysis did not 
account for this confounding 
variable.   
Poor 
CT=C.trachomatis 
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Table 2. Summary of articles for risk factors associated with Chlamydia positivity (cont.) 
Study 
Reference 
Study Design  Source Population Study Population Missing Data Selection Bias Intervention 
Rietmeijer 
et al 2008 
Question: What are 
chlamydia 
positivity rates 
among males 
screened in various 
venues in the US? 
 
Design: Systematic 
literature review 
PubMed Central and US 
National Library of Medicine’s 
online archives, 1995-2007 
 
Search terms ―male,‖ 
―chlamydia,‖ ―screening,‖ 
―prevalence,‖ and ―positivity‖ 
 
Additional manual search 
Limited to asymptomatic 
men in clinical and 
nonclinical sites, excluding 
STD clinic settings 
 
54 articles included for 
review. 
 
Studies collected in US 
 
Due to variability in 
study type, test setting, 
testing methodologies, 
recruitment strategies, 
and reported 
subpopulations, meta-
analysis was not 
possible in meaningful 
analysis.  
Because STD 
testing is standard 
of care in STD 
clinics and in 
symptomatic men, 
these populations 
were appropriately 
excluded for 
screening study.  
Through various 
recruitment strategies 
among studies, urine 
samples from male patients 
were screened for CT using 
NAAT. 
 
 
 
Table 2. Summary of articles for risk factors associated with Chlamydia positivity (cont.) 
Study 
Reference 
Measurement of 
exposure/outcome 
Bias and 
Confounding 
Analysis Results Limitations 
Overall 
quality 
Rietmeijer 
et al 2008 
Abstracted data: 
overall male positivity 
rates, and if available, 
rates for race/ethnicity, 
age group, venue, and 
US region. 
 
Articles abstracted 
using tabular format 
conducted by one 
author, then 
independently verified 
and corrected if needed 
by main author 
 
The main 
investigator is 
employed at the 
Denver Public 
Health 
Department. 
There are no 
details for 
funding source 
or other 
publication bias. 
 
It is not clear 
from article 
alone if a 
standardized 
method was used 
to assess study 
quality and 
internal validity.  
Each category of 
abstracted data was 
tabulated to find: 
Median chlamydia 
positivity rate 
Interquartile range 
Number of 
observations 
 
Limitations and 
heterogeneity of data 
appropriately 
precludes meta-
analysis and formal 
synthesis. 
Overall median Chlamydia positivity 
rates ranged 1.7% to 7.9% 
Test Setting 
 13 juvenile detention centers 
(7.9%) and adult centers (6.8%) 
 11 community outreach setting 
(5.5%) 
 Clinical setting (3.8%) including 
14 male screening, 5 
peds/adolescent, 4 HIV, 2 
Emergency, 3 in other clinic setting 
 6 Military setting (4.5%) 
 12 School-based (4.6%) 
 2 mail-in (1.3%, 2.1%) 
Race/Ethnicity (26 studies) 
 Blacks: 6.7% 
 Asians: 2.2% 
Age group (12 studies) 
 20 to 24: 6.5% 
 <15: 2.3% 
Region (46 studies) 
 South : 6.4% 
 West: 3.8% 
 
5:  
 
Study population: demographics not 
described, recruitment process not 
described 
 
Sampling: various locations and 
settings, no inclusion/exclusion criteria 
described for patient recruitment, 
groups not comparable 
 
Bias and confounding: 
Potential for publication bias was not 
mentioned in article, nor any need for 
adjustment in analysis.  
 
Analysis: Unclear in methodology for 
quality assessment and internal validity 
of study. 
 
Results: Only prevalence reported, no 
measures of statistical significance, 
only generalizable findings and 
inferences made. 
Poor 
CT=C.trachomatis, NAAT=nucleic acid amplification test 
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Table 3. Summary of articles for adverse effects of screening (Key Question 3) 
Study 
Reference 
Study Design  Source Population Study Population 
Missing 
Data 
Selection Bias Intervention 
Campbell R, 
et al, 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Question: Does 
home-based 
screening for 
Chlamydia have an 
adverse effect on 
levels of anxiety, 
depression and self-
esteem in those 
screened? If so, do 
anxiety scores return 
to pre-screening 
levels in those 
receiving negative 
test results? 
 
Design: Cohort and 
cross-sectional study 
using questionnaires 
to assess 
psychosocial 
impacts of screening 
for Chlamydia 
85,300 total 16 – 39 
year old men and 
women registered at 
one of the 27 GPs in 
Bristol and 
Birmingham  
 
Study packs were sent 
between Feb 2001 – Jul 
2002 
 
687 people from 13 
practices invited in 
cohort sample 
1533 people from 12 
practices invited in 
cross-sectional samples 
 
 547 before invitation 
 418 at invitation 
 227 after (-) result 
 
842 people responded 
 218 before invitation 
 397 at invitation 
 227 after (-) result 
 
 338 total men 
o 77 before 
o 167 at invitation 
o 94 after result 
 
Randomly selected using 
fixed proportion in each 
practice using household as 
a unit, and one person in a 
household.  
 
Initially selected twice as 
many 16–25 year olds as 
26–39 year olds but after 
interim analysis in the first 
four practices, included 
only 16–25 year olds to 
increase the number of 
identified cases. 
 
Survey cohort of 
individuals randomly 
sampled from all invited 
for screening. Last 12 
studies independent cross-
sectional samples of 
individuals were selected 
at each of the three time-
points. 
 
 
In the first 4 
GPs, cohort 
response was 
low over time, 
causing 
change in 
study design to 
cross-section 
of population.  
 
After an interim analysis of first 
4 practices, invitations for 
screening were narrowed to 16-
25 year olds. 
 
First 2 practices excluded for 
possibility of influences 
measurements surrounding 
publicity of study, ClasSS 
project. 
 
Non-response was associated 
with practices with higher levels 
of ―deprivation‖ OR = 0.88 
(95% CI 0.80, 0.96; p =0.004), 
adjusted for age, sex, and 
ethnicity. 
 
After deprivation adjustment,  no 
evidence of misrepresentation of 
ethnicity (OR=0.98, 95% CI 
0.92-1.05; p=0.71) 
 
Self-selection potential high – 
more aware of risks, anxious 
about infection can be reflected 
in anxiety levels 
 
Under nationalized system, most 
individuals will have been 
registered with a GP – before 
randomization, can capture study 
population representative of 
source population. 
 
Moderate  external validity 
similar young population – can 
be comparable to US youth 
Survey:  
Hospital Anxiety and 
Depression Scale (HAD) for 
main outcome 
 7 item subscale score 0-
21 
o 0-7 normal 
o 8-10 mild 
o 11 and  > in distress 
 
Rosenburg Self Esteem 
Scale used for possible 
stigmatizing effects of 
screening 
 10 items score 10-40 
 
Survey conducted at three 
time points: baseline one-
month before screening 
invitation, on receipt of 
screening with study packet, 
after receipt of negative test 
result 
 
Invitation letter from GP 
with study pack and 
instructions for home 
collection urine and/or 
vulval swab specimen, 
testing for Chlamydia.  
 
Negative results were 
informed by letter, positive 
results were sent 
appointment for follow-up 
with GP 
 
GP=general practitioner, OR=odds ratio, CI=confidence interval                                  (cont.) 
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Table 3. Summary of articles for adverse effects of screening (cont.) 
Study 
Reference 
Measurement of 
exposure/outcome 
Bias and 
Confounding 
Analysis Results Limitations 
Overall 
quality 
Campbell R, 
et al, 2006 
 
 
 
 
 
Study pack complied with 
European regulations of  
mailing of clinical 
specimens 
 
Acceptability and 
readability of study 
materials explored with 11 
people chosen at random 
from those not selected for 
the prevalence study.  
 
We used the first four 
practices to test methods to 
optimize the response rate: 
randomized different types 
of female swabs, 
questionnaires with or 
without sexual behavior 
questions, timing of letter 
from GP, and reminders, 
effect of a monetary 
incentive 
There is some level of 
self-selection for 
participating in study 
for Chlamydia 
screening. At some 
level, participants have 
some anxiety of disease 
status.  
 
Age and sex can have 
confounding effects as 
perceptions of sexual 
behavior and sexual 
activity changes and 
differs. The study 
addresses these 
confounding effects by 
adjusting for age 
bracket and gender.  
 
They have also 
satisfactorily addressed 
ethnicity, sampling 
probability and 
clustering by practice 
and adjusted 
accordingly in 
analyses.  
Planned to measure response 
in cohort of 1000 individuals, 
randomly sampled from all 
invited to be screened, 
stratified by age group, sex 
and practice.  
 
Because of low response rates, 
in last 12 practices of analysis, 
changed to select independent 
cross-sectional random 
samples of individuals at each 
3 time points, stratified as 
before, but now aged 16-25 
only. 
 
Both cohort and cross-
sectional samples used for 
primary outcome. Mean scores 
for anxiety, depression and 
self-esteem at all three points 
compared using generalized 
estimating equations 
 
Practice was incorporated as a 
fixed effect and sample 
fractions used for weights in 
regression analyses. 
Anxiety 
Male (16-25): 6.52 
Male (26-39): 6.27 
Female (16-25): 8.14 
Female (26-39): 8.28 
 
Depression 
Male (16-25): 3.01 
Male (26-39): 4.12 
Female (16-25): 3.63 
Female (26-39): 4.42 
 
Self-esteem 
Male (16-25): 8.57 
Male (26-39): 8.39 
Female (16-25): 7.46 
Female (26-39): 8.47 
 
Overall anxiety over time:  
Before invitation 0 (95% CI) 
After invitation -0.66 (-1.23, -0.09) 
Negative results -0.99 (-1.60, -0.38) 
Overall p=0.0049, 0=0.012 
interaction with sex 
 
Overall depression over time: 
Before invitation 0 (95% CI) 
After invitation -0.47 (-1.09, 0.15) 
Negative results -0.26 (-0.91, 0.39) 
Overall p=0.25, 0=0.041interaction 
with sex 
 
Overall self-esteem over time:  
Before invitation 0 (95% CI) 
After invitation 0.12 (-0.26, 0.50) 
Negative results -0.13 (-0.57, 0.31) 
Overall p=0.26, 0=0.98 interaction 
with sex 
2: 
 
Study design: 
Also, sampling of 
population 
changed from 
cohort to cross 
sectional. 
However, analysis 
showed 
comparable 
response rates and 
average main 
outcomes  
 
Issues with 
selection bias, but 
still good 
representation of 
youthful 
population in 
registered NHS 
system. 
Questionable 
applicability to US 
population, 
without registered 
health care and 
consistent primary 
health access and 
relationship with 
providers 
 
 
Good 
GP=general practitioner                                     (cont.) 
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Table 3. Summary of articles for adverse effects of screening (cont.) 
Study 
Reference 
Study Design  Source Population Study Population Missing Data Selection Bias Intervention 
 
Kangas, I, 
et al., 2006 
 
Question: Are there 
quantifiable concerns 
related to a test for 
Chlamydia in general 
practice? 
 
Design: Comparative 
cross-sectional study 
comparing psychosocial 
impacts of testing for 
Chlamydia between 
patients with positive 
and negative diagnosis 
 
 
 
Setting: Aarhus County, 
Denmark.  
 
Total Population 640,000; 
274 general practices; 450 
GPs 
 
Source: All C.trachomatis 
samples in Aarhus Co. are 
analyzed in Aarhus 
Univ.Hospital. All 
potential participants 
identified through this 
sample submission. 
Appro. 90% of tests are in 
general practice 
 
Two weeks before study, 
GPs were sent letters to 
participate in recruitment 
process. 249 general 
practices accepted. 
 
 
 
 
 
 
 
 
 
 
Recruitment: During visit 
to GP for Chlamydial 
testing, patients asked by 
GP for permission to mail 
further information and 
questionnaire for study 
participation. 
 
Criteria: Age 18 and 
above. 
 
Dates of recruitment: 18 
March – 31 May 2002 
 
For each positive test 
result, three-four negative 
test results were matched 
by sex. 
 
341 questionnaires 
mailed, with 81.2% 
response. 
 
N=277 
 54 (+) women 
 122 (-) women 
 28 (+) men 
 73 (-) men 
 
Age 18-43, mean age=25, 
median age 24.  
 
Symptoms reported in 
40% of men and 48% of 
women at time of testing. 
 
 
25 general practices 
refused to 
participate, but 
there is no 
description of this 
population, 
however, unlikely 
to have large effect 
on study results 
 
 
 
Does not clarify how 
patients were chosen for 
recruitment—age? Purpose 
of visit? Sexual history? 
 
Self-selection of participants 
– 159 participants refused 
study offer by GP. This can 
be because there is a high 
level of stigmatization or 
embarrassment, biasing 
towards the null. 
 
 18.8% of questionnaires 
were never mailed in. 
Unclear if patients already 
received positive of negative 
diagnosis. Either patients 
forgot, or may have been too 
embarrassed or felt 
stigmatized to continue with 
study.  
 
 
 
 
 
 
 
Questionnaire based 
on identified topics of 
concern in separate 
studies of women: 
stigmatization, 
partner’s reaction, 
future reproductive 
health. 
 
Pre-stamped, pre-
addressed mailed to 
participants within 1 
week of testing. 
 
If no response after 2 
weeks, reminder letter 
sent. 
 
For each question, 
asked if they ―fully 
agreed,‖ ―somehow 
agreed,‖ ―somehow 
disagreed,‖ or ―fully 
disagreed‖ 
 
 
GP=general practitioner                                     (cont.) 
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Table 3. Summary of articles for adverse effects of screening (cont.) 
Study 
Reference 
Measurement of 
exposure/outcome 
Bias and 
Confounding 
Analysis Results Limitations 
Overall 
quality 
Kangas, I, et 
al., 2006 
For recruitment of 
general practices, no 
reminder was sent for 
practices that failed to 
respond 
 
It is up to discretion of 
GP to recruit 
participants of study 
 
Unclear from methods 
if patients consistently 
received questionnaire 
before receiving results 
 
Data manually 
extracted—no mention 
of blinding 
 
Also, as questionnaire 
was created for 
women, unclear if 
these are areas of 
concern for men.  
Probable high 
levels of 
selection bias.  
 
Patients are first 
selected GP who 
either request a 
test or the GP 
deems test 
necessary. Also, 
patients are 
approached by 
their GP to 
participate, and 
answer to 
appease GP and 
minimized 
negative effects 
of test. 
 
Also, unclear if 
all the questions 
were anonymous 
and any 
identifying 
information. 
Again, less likely 
to answer 
honestly.  
 
Unclear if 
patients were 
aware of 
diagnosis—can 
affect 
satisfaction with 
testing.  
 
 
Questionnaire responses 
were dichotomized: an 
answer ―fully agreed‖ or 
―somehow agreed‖ was 
considered ―agreeing‖; 
answers with ―somehow 
disagreed‖ or ―fully 
disagreed‖ as 
―disagreeing‖ 
 
Fisher’s exact two-tailed 
test and χ2 test with 
Yates correction. 
Significance was set to p 
< 0.01, adjusting for 
―multiple testing‖ of the 
questionnaire items. 
 
Mantel-Hansel analysis 
was used to adjust for 
age in subgroup analysis. 
Participants were 
dichotomized into two 
age groups, 18-
25(n=183) and 26-
43(n=94) 
 
Multiple subgroup 
analyses performed, but 
no indication in 
methodology for pre-
determined subgroup 
analysis 
 
SPSS 10.0 and STATA 
SE 8.0 were used. 
 
Of 18 men who never considered STI infection and 
agreed to Chlamydia testing: 
 88.9% satisfied with offer, (p=0.36) 
 5.6% felt stigmatized, (p=0.31) 
 5.6% had no emotional impact, (p=0.30) 
 
Of Chlamydia (+) men (n=28) 
 50% considered test a private affair 
 29% felt stigmatized 
 46% think its embarrassing to talk about test 
     In reaction to (+) test 
 21% felt despair 
 29% embarrassed 
 32% no reaction 
     Relation to partner 
 75% was understanding 
 43% were relieved 
 11% ended 
     Infertility 
 68% Do not consider infertility a problem 
 
Of Chlamydia (-) men (n=73) 
 56% considered test a private affair (p=0.55) 
 18% felt stigmatized (p=0.33) 
 18% think it embarrassing to talk about test 
(p=0.005) 
     In reaction to (-) test 
 4% felt despair (p=0.02) 
 3% embarrassed (p<0.001) 
 34% no reaction (p=0.71) 
     Relation to partner 
 75% was understanding (p=0.89) 
 77% were relieved (p<0.01) 
 0% ended (p=0.006) 
     Infertility 
 81% Do not consider infertility a problem 
(p=0.15) 
 
4:  
sampling method 
and potential for 
selection bias 
 
validity and 
reliability of the 
measurement of 
exposure;  
 
attrition, loss to 
follow-up  
 
identification and 
discussion of 
potential biases 
and confounding 
Fair 
GP=general practitioner                                    (cont.) 
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Table 4. Summary of adverse effects of treatment (Key Question 4) 
Study 
Reference 
Study Design  Study Selection Population Missing Data Intervention 
Measurement of 
exposure/outcome 
 
Lau C, et al, 
2002 
 
Question: Is there a 
difference between 
azithromycin or 
doxycycline in 
efficacy and safety 
in the treatment of c. 
trachomatis 
urethritis and 
cervicities? 
 
Design: Meta-
analysis 
 
 
Search: MEDLINE and Pre-
Medline, HealthSTAR, 
Ovid Full Text, EBM 
reviews: Best Evidence, 
Cochrane Database of 
Systematic Reviews, and 
Database of Abstracts and 
Reviews of Effectiveness, 
and manual search. 
 
Time: 1975-August 2001 
  
MeSH: Chlamydia 
trachomatis and 
doxycycline or 
C.trachomatis and 
Azithromycin 
 
Included if all four met: 
1) RCT designs 
2) Medication regimens of 
oral doxycycline (100mg 
twice a day for 7 days) 
and azithromycin (1 g 
once) 
3) Males >15 years old and 
non-pregnant females 
>15 
4) Follow-up evaluation of 
microbial cure defined as 
negative culture or 
enzyme assay 
 
 
12 trials 
 5 masked 
 7 open-label 
 
 2 studies 
female only 
 6 studies 
male only 
 
1543 participants 
 726 males 
 817 females 
 
Do not mention 
location of 
studies, setting of 
provider care, 
socioeconomic 
status, or other 
demographics 
 
Microbial cure was 
calculated using last 
available follow-up 
 
Intention-to-treat 
approach was used for 
attrition rates based on 
last available follow-up 
 
Patients with 
nongonococcal 
urethritis were used as 
proxies for those 
patients with CT 
infection when 
distinction of infection 
was not made 
 
Subjects lost 
to follow-up were 
excluded from the 
analysis 
 
Various tests were 
used to diagnose 
disease. 
9 studies used culture, 
2 used enzyme 
immunoabsorbent 
assay, and 1 used DNA 
amplification tests. 
 
7 studies were open-
label and 5 were 
double-blinded 
 
Randomization scheme 
is not described for 
included studies.  
 
Efficacy difference (ED) 
in cure rate between 
azirthmycin and 
doxycycline was 
computed for each trial 
(treatment success/all 
subjects who began 
treatment) 
 
Treatment success = 
number of subjects 
assigned to a particular 
antibiotic group who 
complied with treatment 
regimen and cured at 
follow-up.  
 
There is no discussion on 
how information on 
adverse effects were 
tallied and scored. There 
is no mention is this was 
questionnaire, interview, 
and if this was made 
anonymous. Also, 
because of inconsistency 
of reporting, further 
analysis was not 
performed. 
 
 
 
                                                                            (cont.) 
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Table 4. Summary adverse effects of treatment (cont.) 
Study 
Reference 
Bias and 
Confounding 
Analysis Results Limitations 
Overall 
quality 
 
Lau CY, et 
al, 2002 
 
A stratified meta-
analysis was 
performed to assess 
possible bias in the 
results. Data were 
stratified by various 
subgroups: type of 
diagnostic assay 
(culture/nonculture), 
sex (male/female), 
attrition rate, 
follow-up time, 
publication date, 
study design 
(open/blind) and 
study sponsorship 
 
Begg’s and Egger’s 
tests were used to 
check for 
publication bias in 
pooled estimates. 
To increase 
statistical power, a 
P value of 0.10 was 
used as the criterion 
for determining 
statistical 
significance of the 
tests for publication 
bias. 
 
Dichotomous outcomes 
(microbial cure versus no 
microbial cure) were pooled 
by calculating overall 
weighted average of the ED 
from each trial by assigning 
weights derived from the 
standard error of the ED. 
 
A similar approach was 
used to calculate the pooled 
risk difference (RD) of 
adverse events for the two 
antibiotics 
 
Each pooled RD and ED 
was tested for statistical 
significance, and 95% CIs 
were computed. In 
computing the pooled 
estimates, it was assumed 
that ED and RD were 
uniform across trials and 
that differences in results of 
individual trials could be 
attributed to chance. Hence, 
a fixed effects model was 
used. A chi-square test of 
homogeneity was used to 
test the assumption of 
uniform ED and RD.  
 
Azithromycin group 
 microbial cure in 853 of 884 patients 
(96.5%) 
 adverse events were reported by 319 of 
1274 (25.0%) 
 
Doxycycline group 
 microbial cure in 645 of 659 patients 
(97.9%). 
 adverse events were reported by  205 of 
897 (22.9%) 
 
Pooled ED for microbial cure of azithromycin 
versus doxycycline is 0.008 (95% CI, -0.007–
0.022) with (Z =1.05; P=0.296). 
 
Test for homogeneity shows that results for 
individual trials are consistent with overall 
pooled ED (χ
2
=10.48; df=11; P=0.488). 
 
RD for an adverse event is 0.009 (95% CI, -
0.019–0.037) with Z =0.62; P=0.533) 
 
Test for homogeneity shows that the results are 
consistent across trials (χ
2
= 6.63; df =8; P = 
0.577).  
 
Most frequently reported adverse events were 
gastrointestinal in nature (87.3%) including 
diarrhea, abdominal pain, nausea, vomiting, 
dyspepsia, constipation, and flatulence. 
 
Nongastrointestinal symptoms included fatigue, 
malaise, sweating, dizziness, headache, skin 
rash, drug eruption and other unspecified events 
 
 
4: 
 
Study population: 
There was not much description of 
the study populations of the 
individual trials.  
 
Missing data: Excluding all data 
from those lost to follow-up cause 
an error that underestimates 
adverse effects, or decreases 
detection of adverse effects, 
although this may be minimal. 
 
Also, by using nongonococcal 
urethritis as proxies for CT 
infections, the investigators have 
increased likelihood of detecting 
adverse event from treatment 
regimens. Treatment is the same, 
and should have similar profile for 
adverse events 
 
Exposure measurement: it is not 
clear what tools were used to 
diagnose Chlamydia in individual 
trials, and how study participants 
were randomized to study arms. 
The review is not clear in their 
methodology for appraising studies 
and discussing findings.  
 
Fair 
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